REPORTING SEASON CALENDAR

August 2026.

Contents | Pages

REPORTING SNAPSHOT.

Date	Company
Mon 3 Aug	INR
Tue 4 Aug	COF, VFY
Wed 5 Aug	**LNW**
Thu 6 Aug	BPT, KYP, **REA**
Fri 7 Aug	AVH, NCK
Sun 9 Aug	AR1
Mon 10 Aug	**CAR**, DXC
Tue 11 Aug	**360**, C79, CIP, CRN, **SGH**
Wed 12 Aug	DXI, EBR
Thu 13 Aug	HDN, ONE, **TLS**
Fri 14 Aug	IPG, PMT, SKG
Mon 17 Aug	**A2M**, DOC, IMD, **JBH**
Tue 18 Aug	AEL, AHL, APZ, CGS, **CSL**, HCW, **HUB**, **PME**, RGN, **SEK**, SRG
Wed 19 Aug	EOL, **EVN**, STP, SXE, TPW, **WHC**
Thu 20 Aug	ALK, BGA, CCL, CDA, EGL, FEX, **GMD**, **GMG**, MVP, NOU, PWH, RFG, **SHL**, **TLX**, UNI, WRK
Fri 21 Aug	AMA, AX1, DGT, EOS, GYG, ING, LGI, LIC, RFF, **RRL**
Mon 24 Aug	ABY, ADH, **FMG**, GDI, GLF, KGN, MVF, PFP, **PLS**, RPL
Tue 25 Aug	AL3, **COL**, CWP, GNP, IDX, MAD, MND, NAN
Wed 26 Aug	AHC, ALC, COG, CUV, DMP, DRO, ELS, FHE, HMC, IGL, LOV, NIC, NWL, PNV, **WOW**, **WTC**
Thu 27 Aug	**APE**, BLX, BUB, CCV, CNI, GDG, IRI, JIN, **MIN**, MYG, NEU, **PDN**, PGC, **SIG**, SIQ, SLD, SNS, SNT, SNZ, TRJ
Fri 28 Aug	ASB, AUC, AV1, AVR, AYA, BOE, CYC, EMV, HVN, IMM, IPD, ITS, LDX, MMS, PYC
Mon 31 Aug	4DX, CU6, CVL, EIQ, FLC, IMU, LTR, MSB, PAR, RAD, RIV, RMY

Bolded stocks represent S&P/ASX 100 constituents.

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

REPORTING CALENDAR CHRONOLOGICAL ORDER.

							EBITDA Forecast ($m)		Adjusted NPAT Forecast ($m)		Adjusted EPS Forecast (cents)		DPS Forecast (cents)		
Report Date *(* Estimate)*	Code	Price	Reporting Year End	Analyst	Target Price	Recommendation	HY26	FY26	HY26	FY26	HY26	FY26	Interim HY26 Dividend	Final FY26 Dividend	Comments
30/07/2026*	CIA	3.31	HY	Stuart Howe	$3.40	Hold	-	-	-	-	-	-	-	-	Mar YE. Q1 FY27 reported -C$42m adjusted net loss. Next release dates: AGM 26 Aug; Q2 FY27 29 Oct.
3/08/2026	INR	$0.11	FY	Stuart Howe	$0.40	Buy (Spec)	-	-10.0	-	-4.0	-	6.7	-	-	Project development company, result not relevant to investment view. Catalyst: Project level sell-down progress.
4/08/2026	COF	$0.91	FY	Michael Armstrong	$0.95	Hold	58.1	115.5	33.4	67.0	5.6	11.2	5.1	10.1	Looking for commentary on office lease-up, particularly within the challenged Docklands and St Leonards markets. Potential for COF to lower its dividend in FY27 as currently it is not cash earnings covered.
04/08/2026*	VFY	$3.70	FY	Martyn Jacobs	$5.15	Buy (Spec)	-	-17.8	-	-17.1	-	-22.4	-	-	Pre-revenue company, with primary focus on attaining FDA clearance by end of CY26 for blood patelets and Red Blood Cells, and continuing to build market interest in its Cryopreservation technology.
5/08/2026	LNW	$115.97	HY	Baxter Kirk	$190.00	Buy	-	367.5	-	114.5	-	143.8	-	-	2Q26 - Management has previously guided to a 2H EBITDA growth skew
6/08/2026	BPT	$0.91	FY	Stuart Howe	$0.95	Hold	-	937.3	-	379.6	-	16.6	1.0	2.0	Downside risk to DPS (capital management review underway) and to FY27 guidance to be issued with result (BP est. 21.4mmboe).
6/08/2026	KYP	$0.15	FY	Chris Savage	$0.36	Buy	-	5.5	-	2.0	-	0.5	-	-	Forecasts are statutory.
6/08/2026	REA	$160.00	FY	Michael Ardrey	$137.00	Sell	-	1,043.8	-	625.5	-	475.5	124.0	266.3	Strong listings late in FY26 providing some momentum into early FY27 ; expecting outlook to focus on listings and margin against a challenging operating environment
07/08/2026*	AVH	$1.29	HY	John Hester	$1.20	Hold (Spec)	-15.4	-	-19.9	-	-58.0	-	-	-	Expecting strong recover in revenues following resolution on MACS reimbursement

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Report Date (* Estimate)	Code	Price	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m) HY26	EBITDA Forecast ($m) FY26	Adjusted NPAT Forecast ($m) HY26	Adjusted NPAT Forecast ($m) FY26	Adjusted EPS Forecast (cents) HY26	Adjusted EPS Forecast (cents) FY26	DPS Forecast (cents) Interim HY26 Dividend	DPS Forecast (cents) Final FY26 Dividend	Comments
7/08/2026	NCK	$16.05	FY	Chami Ratnapala	$22.00	Buy	-	180.8	-	75.7	-	88.6	39.0	60.9	BPe ~2% below Consensus at NPAT level for FY26e
09/08/2026*	AR1	$0.06	HY	David Coates	$0.17	Buy	-	$57m	-	41.0	-	1.6	-	-	Transitioning to production, cash $83m
10/08/2026	CAR	$25.98	FY	Michael Ardrey	$34.60	Buy	-	709.8	-	406.1	-	107.4	42.5	80.6	Consensus adj. NPAT (cc) growth currently below CAR guidance; positive result ahead of market expectations could meet large short position (11.5%)
10/08/2026	DXC	$2.67	FY	Michael Armstrong	$3.15	Buy	19.5	39.2	14.5	28.8	10.5	20.9	10.5	20.9	Expect commentary around fund-through development pipeline/further opportunities, tenant health, and the ongoing 5% on-market share buyback. Expect soft FY27 earnings guidance predicated on elevated interest rates.
11/08/2026	360	$25.56	HY	Chris Savage	$35.00	Buy	42.8	-	40.1	-	15.1	-	-	-	Forecasts are in USD/USC. EBITDA forecast is adjusted.
11/08/2026	C79	$5.96	FY	Joseph House	$7.80	Buy	-	29.4	-	2.5	-	2.1	-	-	FY27 revenue guidance will be highly anticipated to affirm deployment expectations. Restoration of confidence in the deployment outlook is key for C79.
11/08/2026	CIP	$3.01	FY	Andy MacFarlane	$3.60	Buy	88.9	180.1	57.3	115.7	9.1	18.5	8.4	16.8	FY26 guidance for FFO / share of 18.2-18.5c (increased bottom end at 1Q26) and DPS of 16.8c
11/08/2026	CRN	$0.18	HY	James Williamson	$0.17	Sell (Spec)	-	-86.3	-	-226.8	-	-13.5	-	-	All figures in US$.
11/08/2026	SGH	$44.43	FY	Joseph House	$50.00	Buy	-	2,104.2	-	952.1	-	233.1	32.0	66.0	Consensus FY27 EBIT growth is low-to-mid single-digit. We expect FY27 Group EBIT growth guidance to be consistent with consensus.
12/08/2026	DXI	$2.47	FY	Andy MacFarlane	$3.00	Buy	37.9	75.2	28.2	55.1	8.9	17.4	8.3	16.6	FY26 guidance is for FFO / share of 17.4c and DPS of 16.6c; BPe and VA consensus both in line

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Report Date (* Estimate)	Code	Price	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m) HY26	EBITDA Forecast ($m) FY26	Adjusted NPAT Forecast ($m) HY26	Adjusted NPAT Forecast ($m) FY26	Adjusted EPS Forecast (cents) HY26	Adjusted EPS Forecast (cents) FY26	DPS Forecast (cents) Interim HY26 Dividend	DPS Forecast (cents) Final FY26 Dividend	Comments
12/08/2026*	EBR	$0.27	HY	Martyn Jacobs	$0.90	Buy (Spec)	-30.0	-52.0	-34.0	-59.6	-4.5	-7.0	-	-	1H26 should be peak operating loss. Focus will be on growth in utilisation and progress in deployment to announced hospital contracts.
13/08/2026	HDN	$1.27	FY	Michael Armstrong	$1.25	Sell	134.7	273.6	92.3	188.5	4.4	9.0	4.3	8.6	Management have previously commented on slowing the annual development starts from $100-$120m to $50-60m, which will limit earnings growth.
13/08/2026*	ONE	$0.17	HY	Martyn Jacobs	$0.42	Buy (Spec)	-4.0	-7.9	-4.5	-9.0	-0.5	-1.0	-	-	Aiming for >20% top line growth while continuing to narrow operating losses.
13/08/2026	TLS	$5.02	FY	Chris Savage	$5.10	Hold	-	8,966.0	-	2,328.7	-	20.6	-	10.5	EBITDA, NPAT and EPS forecasts are underlying.
14/08/2026	IPG	$4.80	FY	Joseph House	$6.20	Buy	-	55.0	-	30.5	-	29.3	6.8	14.6	FY27 guidance to be qualitative rather than quantative and focussing on strong momentum in the Data Centre market.
14/08/2026*	PMT	$0.42	HY	Stuart Howe	$0.97	Buy (Spec)	-	-	-	-	-	-	-	-	Project development company, result not relevant to investment view. Catalyst: Project permitting & optimisation updates.
14/08/2026	SKG	$1.30	FY	Michael Armstrong	$1.50	Hold	60.4	124.1	40.4	81.5	3.1	6.2	3.1	6.2	Looking for clarity regarding ABG's 20% stake and the 40% stake held by the Kirsch family. At announcement of the de-staple, SKG guided to +6% earnings growth on cost savings.
17/08/2026	A2M	$6.86	FY	Jonathan Snape	$6.90	Hold	-	234.9	-	168.8	-	23.2	8.2	60.2	FY26e Revenue guidance of NZ$1.93-2.02Bn, with an EBITDA margin of 14.0-14.5%
17/08/2026	DOC	$0.11	HY	John Hester	$0.24	Buy	2.6	-	0.5	-	0.1	-	-	-	Progress on recently completed acquistion should be interesting
17/08/2026	IMD	$3.75	FY	Joseph House	$4.60	Buy	-	157.1	-	55.1	-	10.2	1.7	3.2	Expecting FY27 outlook to be generally positive; focus will be on cost and margin expectations.
17/08/2026	JBH	$82.42	FY	Chami Ratnapala	$87.00	Buy	-	1,000.4	-	482.8	-	438.5	210.0	330.6	BPe ~1% below Consensus for FY26e

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Report Date (* Estimate)	Code	Price	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m)		Adjusted NPAT Forecast ($m)		Adjusted EPS Forecast (cents)		DPS Forecast (cents)		Comments
							HY26	FY26	HY26	FY26	HY26	FY26	Interim HY26 Dividend	Final FY26 Dividend	
18/08/2026	AEL	$1.51	FY	Stuart Howe	$2.50	Buy	-	196.8	-	47.2	-	17.5	-	-	East Coast Supply Project exploration success and development updates the key catalyst. Juliet exploration results due mid-Aug'26. FY26 earnings less relevant.
18/08/2026	AHL	$1.16	FY	Chris Savage	$1.35	Hold	-	19.4	-	5.9	-	7.3	-	2.2	EBITDA forecast is underlying. NPAT and EPS forecasts are statutory.
18/08/2026	APZ	$5.17	FY	Andy MacFarlane	$6.50	Buy	26.3	54.2	24.3	48.2	10.7	21.2	5.5	11.0	FY26 guidance is for 21.5c pre-tax EPS; Key markets in WA and SA continue to perform well; looking for margin expansion and update on BTR book
18/08/2026	CGS	$2.51	FY	Thomas Wakim	$3.70	Buy	-	17.3	-	10.9	-	6.3	-	2.0	All figures in USD except DPS. Only specific FY26 guidance is 2H26 GM 56-59%.
18/08/2026	CSL	$124.30	FY	Thomas Wakim	$120.00	Hold	-	5,246.0	-	3,104.0	-	638.3	130.0	160.0	All figures in USD. BPe in line with FY26 guidance of NPATA $3.1b. We forecast further earnings decline (-7%) in FY27 vs consensus at +1%.
18/08/2026	HCW	$0.75	FY	Andy MacFarlane	$0.95	Buy	22.7	43.2	12.3	22.9	2.2	4.2	-	-	No FY26 guidance given current HSO situation. We assume UHF and HCW distribution to turn back on in 2Q27
18/08/2026	HUB	$85.71	FY	Hayden Nicholson	$110.00	Buy	-	213.1	-	130.9	-	157.3	-	42.1	FY26 group operating expenses expected to increase +18-20%. We expect custodial FUA targets to be rolled forward to FY28 (Bell Potter $192.7bn).
18/08/2026	PME	$164.69	FY	John Hester	$226.00	Buy	-	195.1	-	138.4	-	138.5	32.0	70.0	Focus will be on timing of revenues from the two major new clients
18/08/2026	RGN	$2.40	FY	Andy MacFarlane	$2.75	Buy	125.9	255.4	91.4	184.9	7.9	16.0	6.9	14.1	Strong treasury has put RGN in good stead, with new CEO Greg Chubb joining during the period
18/08/2026	SEK	$14.68	FY	Michael Ardrey	$18.58	Buy	-	541.6	-	200.1	-	56.0	27.0	52.0	Job ad volumes to be soft, potential for price to provide positive result. Margin and potential for Growth Fund realisation to support result/outlook

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Report Date (* Estimate)	Code	Price	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m)		Adjusted NPAT Forecast ($m)		Adjusted EPS Forecast (cents)		DPS Forecast (cents)		Comments
							HY26	FY26	HY26	FY26	HY26	FY26	Interim HY26 Dividend	Final FY26 Dividend	
18/08/2026	SRG	$3.38	FY	Joseph House	$4.25	Buy	-	167.2	-	74.0	-	12.9	3.0	6.5	FY27 EBITDA guidance was initially set in June 2026. We anticipate this guidance to be reiterated.
19/08/2026*	EOL	$14.51	FY	Ritesh Varma	$17.10	Buy	-	21.3	-	9.6	-	30.4	-	12.0	ARR growth is the key measure here, guided to 13% in May.
19/08/2026	EVN	$11.46	FY	David Coates	$15.10	Buy	-	3,696.2	-	1,976.4	-	95.9	20.0	50.0	Watch for upside dividend surprise vs consensus 43c
19/08/2026	STP	$0.15	FY	Leo Armati	$0.29	Hold	-	0.4	-	0.1	-	-	-	-	Key focus on GM given pullback in promotional spend (BPe 72.1% vs. 76.4% in pcp) Inventory management given expansion in product range and SKU's
19/08/2026	SXE	$4.38	FY	Joseph House	$5.40	Buy	-	75.3	-	42.0	-	15.7	2.5	8.5	FY27 EBITDA guidance was initially set in June 2026. We anticipate this guidance to be reiterated.
19/08/2026	TPW	$5.55	FY	Chami Ratnapala	$7.00	Buy	-	21.3	-	8.4	-	6.5	-	-	Guidance of $665-675m in revenue (up 11% to 12%) and EBITDA of $20-22m for FY26
19/08/2026	WHC	$7.05	FY	James Williamson	$8.05	Hold	-	1,321.3	-	282.5	-	34.2	-	7.0	Expect equal $ value of dividend allocated to share buy-back (i.e. $55m dividend; $55m share buy-back)
20/08/2026	ALK	$1.31	FY	David Coates	$2.10	Buy	-	473.0	-	238.4	-	17.4	-	-	First year of merger with Mandalay
20/08/2026	BGA	$6.14	FY	Jonathan Snape	$7.75	Buy	-	224.7	-	69.9	-	22.9	7.0	14.0	FY26e EBITDA guidance of $222-227m
20/08/2026	CCL	$5.06	FY	Hayden Nicholson	$5.80	Buy	-	76.1	-	44.0	-	22.6	-	5.3	1H26 NPAT is expected to be 55% of FY26, implying $44m guidance based on high-single-digit volume growth.
20/08/2026*	CDA	$40.08	FY	Baxter Kirk	$41.30	Hold	-	275.3	-	169.9	-	93.6	19.5	46.8	-

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

BELL POTTER REPORTING SEASON CALENDAR AUGUST 2026

Report Date (* Estimate)	Code	Price	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m)		Adjusted NPAT Forecast ($m)		Adjusted EPS Forecast (cents)		DPS Forecast (cents)		Comments
							HY26	FY26	HY26	FY26	HY26	FY26	Interim HY26 Dividend	Final FY26 Dividend	
20/08/2026*	EGL	$0.10	FY	Ritesh Varma	$0.21	Buy	-	8.6	-	3.1	-	0.8	-	-	Following guidance downgrade in May, we look for FY27 guidance.
20/08/2026*	FEX	$0.26	FY	James Williamson	$0.54	Buy	-	80.4	-	9.9	-	1.3	-	-	Potential for modest dividend contingent upon board discretion.
20/08/2026*	GMD	$5.83	FY	Todd Lewis	$9.20	Buy	561.5	1,004.3	325.7	581.4	28.6	51.0	-	-	Beat on produciton, miss on costs. Look for merger with Vault as a key cataly in late 2026.
20/08/2026	GMG	$29.87	FY	Andy MacFarlane	$35.50	Buy	1,172.3	2,758.0	1,203.5	2,670.0	58.5	129.7	15.0	30.0	We forecast a small beat to guidance (10% vs. 9%) driven by profits booked on land uplift for DC projects going into WIP, as well as transaction relisation (Moorrabbin).
20/08/2026*	MVP	$0.43	FY	Martyn Jacobs	$1.00	Buy	-	1.0	-	-1.5	-	-1.4	-	-	Focus on completion of EU expansion in labelling, Australian healthcare economic analysis and outlook for rev. / earnings growth.
20/08/2026	NOU	$0.12	FY	Jonathan Snape	$0.12	Hold	-	64.4	-	37.0	-	13.4	-	-	EBITDA guidance of $61-63m
20/08/2026	PWH	$9.98	FY	Chris Savage	$9.25	Hold	-	39.4	-	15.8	-	15.7	-	4.5	Forecasts are statutory.
20/08/2026*	RFG	$0.86	FY	Chami Ratnapala	$0.74	Hold (Spec)	-	20.0	-	5.4	-	8.7	-	-	Guidance of Und.EBITDA at $20-21m for FY26
20/08/2026	SHL	$21.84	FY	Martyn Jacobs	$28.75	Buy	-	1,962.0	-	661.6	-	129.1	45.0	109.0	Slightly above consensus EBITDA at $1.934b. Initiatives from US operaitonal review, margin management and further indications on sale&leaseback opportunities.
20/08/2026	TLX	$14.28	HY	John Hester	$19.00	Buy	44.9	-	26.6	-	-	7.8	-	-	Revenues pre released, focus will be on cash and clinical update
20/08/2026	UNI	$7.39	FY	Chami Ratnapala	$10.50	Buy	-	104.0	-	39.8	-	50.7	26.0	36.9	Guidance of $61.5-64.5m EBITA for FY26

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Report Date (* Estimate)	Code	Price	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m)		Adjusted NPAT Forecast ($m)		Adjusted EPS Forecast (cents)		DPS Forecast (cents)		Comments
							HY26	FY26	HY26	FY26	HY26	FY26	Interim HY26 Dividend	Final FY26 Dividend	
20/08/2026	WRK	$0.07	FY	Hayden Nicholson	$0.12	Buy (Spec)	-	-5.6	-	-7.6	-	-0.4	-	-	EBITDA estimates are before share based payments. FY26 EBITDA is expected to be -$6m.
21/08/2026	AMA	$0.46	FY	Chris Savage	$1.00	Buy	-	68.4	-	5.8	-	1.2	-	-	EBITDA forecast is normalised pre AASB 16. NPAT and EPS forecasts are statutory post AASB 16.
21/08/2026	AX1	$0.71	FY	Chami Ratnapala	$0.80	Hold	-	281.1	-	34.4	-	5.7	3.3	3.9	Guidance of EBIT $79.5-84.5m for FY26
21/08/2026	DGT	$2.57	FY	Andy MacFarlane	$3.40	Buy	57.2	124.9	43.4	73.9	7.9	13.4	6.0	12.0	FY26 guidance underlying EBITDA $125m, growth capex $160-180m, DPS 12c (90-100% payout), and 85mw IT contracted.
21/08/2026*	EOS	$6.94	FY	Baxter Kirk	$12.60	Buy	20.7	-	10.0	-	-	4.8	-	-	Excludes acquisition costs.
21/08/2026	GYG	$25.33	FY	Leo Armati	$24.50	Buy	-	85.1	-	21.1	-	20.8	7.4	7.3	FY26 guidance: Australia segment underlying EBITDA $85m, +29% on pcp). To look for: First 7-weeks trading update SSSG (cycling +3.7%)
21/08/2026	ING	$2.19	FY	Jonathan Snape	$2.10	Hold	-	188.6	-	58.7	-	19.6	4.0	10.0	FY26e EBITDAL guidance of $180-210m and includes $7m of additional distribution costs
21/08/2026	LGI	$2.39	FY	Ritesh Varma	$4.50	Buy	-	21.6	-	8.7	-	8.8	-	2.6	With low commodity prices, FY27 EBITDA guidance will be interesting.
21/08/2026	LIC	$5.18	FY	Andy MacFarlane	$5.50	Hold	22.4	50.8	9.5	28.9	7.8	23.8	-	-	Looking for direction / confidence on FY27 settlements, possible guidance, and any improvement (if so) on the market outlook.
21/08/2026*	RFF	$2.19	FY	Jonathan Snape	$2.50	Buy	-	78.8	-	45.8	-	11.8	5.9	11.7	FY26 AFFO guidance of 11.72pu
21/08/2026	RRL	$6.15	FY	David Coates	$8.45	Buy	-	1,511.8	-	831.0	-	109.7	15.0	34.0	Higher costs and investment CAPEX in FY27

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Report Date (* Estimate)	Code	Price	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m)		Adjusted NPAT Forecast ($m)		Adjusted EPS Forecast (cents)		DPS Forecast (cents)		Comments
							HY26	FY26	HY26	FY26	HY26	FY26	Interim HY26 Dividend	Final FY26 Dividend	
24/08/2026	ABY	$0.25	FY	Leo Armati	$0.39	Hold	-	4.0	-	-0.8	-	-0.0	-	-	FY26 guidance: Underlying EBITDA of $4.0m and 2H26 GM of 34.5%. To look for: NDC progress and FY27 commentary
24/08/2026	ADH	$1.39	FY	Chami Ratnapala	$1.45	Hold	-	68.3	-	33.8	-	19.0	5.5	9.9	Guidance of $53.5-55.5m EBIT (Pre-AASB 16) for FY26
24/08/2026	FMG	$17.80	FY	David Coates	$17.40	Hold	-	8,504.0	-	3,827.3	-	122.7	62.0	113.0	Downside risk on higher costs (diesel), FX and pric realisations
24/08/2026	GDI	$0.63	FY	Andy MacFarlane	$0.85	Buy	31.0	62.2	21.3	42.0	3.9	7.8	2.5	5.0	FY26 guidance is for DPS of 5.0c (through-cycle target; already met), looking for updates on potential asset disposals, performance of Co-Living JV, and potential Broadmeadows perf fee.
24/08/2026	GLF	$4.47	HY	Andy MacFarlane	$5.65	Buy	67.9	137.8	56.4	113.0	14.8	29.7	1.1	2.0	Key focus for the market will be commentary on sales and settlements achieved (CY26 guidance 420 lots; BPe 425 lots), and margin support.
24/08/2026	KGN	$4.26	FY	Chami Ratnapala	$3.30	Hold	-	40.8	-	18.2	-	17.4	8.0	12.8	Guidance of Group Adjusted EBITDA margins of 6-9% for FY26
24/08/2026	MVF	$0.69	FY	Martyn Jacobs	$0.75	Hold	-	51.4	-	15.1	-	4.3	1.2	2.3	Pre-released guidance downgrade. Focus will be on stabiling the business and improving the key Victorian segment. Cost out initiative potential to improve profitability.
24/08/2026	PFP	$3.27	FY	Chami Ratnapala	$3.80	Buy	-	54.6	-	19.5	-	14.1	7.5	11.9	Guidance of $225-230m in revenue and $54.5-56.5m in operating EBITDA for FY26
24/08/2026	PLS	$4.08	FY	James Williamson	$4.70	Hold	-	1,148.3	-	563.9	-	17.5	-	4.0	See potential for modest dividend with strong cash generation, although at risk with potential large capital investment program with P2000 Project.
24/08/2026	RPL	$2.78	HY	Hayden Nicholson	$4.80	Buy	151.0	-	90.0	-	24.4	-	7.0	-	Guidance floor of at least $110m in management fees, $115m in performance fees, and $90m NPAT.

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Report Date (* Estimate)	Code	Price	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m) HY26	EBITDA Forecast ($m) FY26	Adjusted NPAT Forecast ($m) HY26	Adjusted NPAT Forecast ($m) FY26	Adjusted EPS Forecast (cents) HY26	Adjusted EPS Forecast (cents) FY26	DPS Forecast (cents) Interim HY26 Dividend	DPS Forecast (cents) Final FY26 Dividend	Comments
25/08/2026*	AL3	$0.12	FY	Stuart Howe	$0.35	Buy (Spec)	-	-2.0	-	-3.0	-	-0.5	-	-	Project development company, result not relevant to investment view. Catalyst: Commercial agreement & market updates.
25/08/2026	COL	$24.27	FY	Jonathan Snape	$22.80	Hold	-	4,220.5	-	1,194.8	-	89.0	41.0	75.0	No guidance, 4Q revenue expected to be bolstered by supplier price increase requests
25/08/2026	CWP	$6.85	FY	Andy MacFarlane	$9.30	Buy	62.2	99.4	39.6	63.3	47.9	76.7	14.0	38.0	Our bottom up analysis has CWP recording 1,100 settlements in FY26, growing to c. 1,183 in FY27. Interested in equiry/sales levels following May '26 budget changes and forecasts for FY27 sales
25/08/2026	GNP	$8.85	FY	Joseph House	$12.80	Buy	-	97.2	-	52.6	-	28.2	2.0	6.5	Given guidance was upgraded in late FY26, we have high confidence in our FY26 estimates. We are expecting FY27 organic EBITDA growth of ~22%.
25/08/2026	IDX	$2.14	FY	Martyn Jacobs	$3.80	Buy	-	172.0	-	49.7	-	13.3	3.3	8.3	BPe is slightly above consensus EBITDA ($169m). Focus on incremental MRI contribution and Lung cancer screening, with achievement of 21% margin guidance and cost mitigation. First briefing from new CEO to set agenda.
25/08/2026	MAD	$6.97	FY	Joseph House	$9.70	Buy	-	121.3	-	67.2	-	32.8	4.8	5.5	Focus will be on FY27 revenue and NPAT guidance. BPe is $1,114m and $76m, respectively.
25/08/2026	MND	$29.55	FY	Joseph House	$32.00	Hold	-	224.0	-	126.6	-	126.1	49.0	105.0	Revenue outlook likely to be qualitative. Focus will be on comments relating to tendering activity and operating margin expectations.
25/08/2026	NAN	$3.18	FY	John Hester	$3.60	Hold	-	22.9	-	15.9	-	5.2	-	-	Expecting another lack lustre result with modest revenue growth only
26/08/2026*	AHC	$0.23	FY	Martyn Jacobs	$0.45	Buy	-	14.3	-	9.0	-	2.4	-	-	Guidance previously downgraded reflecting sectoral and macro events. Market will be looking for whether headwids have eased.
26/08/2026*	ALC	$0.09	FY	Thomas Wakim	$0.15	Buy	-	5.8	-	1.0	-	0.1	-	-	Revenue pre-released at quarterly. EBITDA guidance is >$5m.

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Report Date (* Estimate)	Code	Price	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m) HY26	EBITDA Forecast ($m) FY26	Adjusted NPAT Forecast ($m) HY26	Adjusted NPAT Forecast ($m) FY26	Adjusted EPS Forecast (cents) HY26	Adjusted EPS Forecast (cents) FY26	DPS Forecast (cents) Interim HY26 Dividend	DPS Forecast (cents) Final FY26 Dividend	Comments
26/08/2026	COG	$1.38	FY	Hayden Nicholson	$2.10	Buy	-	48.3	-	29.9	-	14.4	-	3.5	EBITDA and NPAT estimates are ex-minorities.
26/08/2026*	CUV	$9.16	FY	Thomas Wakim	$17.00	Buy	-	42.2	-	36.2	-	71.8	-	5.0	Company doesn't provide guidance.
26/08/2026	DMP	$19.73	FY	Leo Armati	$18.50	Hold	-	338.2	-	120.3	-	127.2	25.0	25.0	FY26 guidance: Underlying NPAT b/w $118-$122m (BPe $120.3m) To look for: First 7-weeks trading update SSSG (cycling -0.9%)
26/08/2026	DRO	$1.82	HY	Baxter Kirk	$2.50	Buy	1.3	-	-6.8	-	-0.7	-	-	-	Revenue and Gross margin pre-reported and CY26 guided in late July 2026. Focus will be on the degree of the scaling cost base.
26/08/2026*	ELS	$6.17	HY	Baxter Kirk	$8.20	Buy	10.7	-	9.2	-	3.8	-	-	-	10.7 EBIT not EBITDA. BPe underlying NPAT incl. SBC. Revenue and cash costs pre reported.
26/08/2026*	FHE	$0.19	HY	Ritesh Varma	$0.35	Buy	-2.0	-	-1.8	-	-0.3	-	-	-	Looking at development timeline commentary and debt financing.
26/08/2026	HMC	$2.98	FY	Andy MacFarlane	$3.20	Hold	49.6	178.8	29.1	118.6	7.1	28.7	6.0	12.0	Looking through FY26, where guidance for pre-tax EPS of at least 40c (BPe 40c; VA cons 38.6c), wins for DGT (potential capital distribution), Healthscope approaching resolution, we see HMC turning the corner post challenging 12-24mths.
26/08/2026	IGL	$2.85	FY	Chris Savage	$3.25	Buy	-	153.5	-	52.2	-	33.5	-	8.5	EBITDA, NPAT and EPS forecasts are underlying.
26/08/2026*	LOV	$24.75	FY	Chami Ratnapala	$33.50	Hold	-	287.9	-	90.6	-	81.2	53.0	78.9	BPe ~8% below Consensus at EBIT level for FY26e
26/08/2026	NIC	$0.82	FY	David Coates	$1.45	Buy	255.0	604.0	126.0	316.0	2.9	7.3	-	-	Balance sheet deleveraging story CY27

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Report Date (* Estimate)	Code	Price	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m)		Adjusted NPAT Forecast ($m)		Adjusted EPS Forecast (cents)		DPS Forecast (cents)		Comments
							HY26	FY26	HY26	FY26	HY26	FY26	Interim HY26 Dividend	Final FY26 Dividend	
26/08/2026	NWL	$22.43	FY	Hayden Nicholson	$30.00	Buy	-	195.3	-	132.4	-	54.0	-	23.0	FY26 EBITDA margins expected to land at 49%, with $12m invested in capitalised software.
26/08/2026	PNV	$0.88	FY	John Hester	$1.00	Hold	-	8.2	-	3.8	-	0.6	-	-	Growth rate really slowed in 2H26, stock has de-rated
26/08/2026	WOW	$40.14	FY	Jonathan Snape	$35.50	Hold	-	6,119.9	-	1,509.5	-	123.6	45.0	91.0	1) Australian Food EBIT is expected to grow at mid-high single digit rates; and (2) 2H26e NZ EBIT is expected to be modestly down YoY in NZD terms
26/08/2026	WTC	$36.74	FY	Chris Savage	$71.75	Buy	-	561.0	-	160.4	-	69.0	-	8.0	Forecasts are in USD/USC. Forecasts are statutory.
27/08/2026	APE	$23.85	HY	Chris Savage	$28.00	Buy	431.2	-	128.1	-	44.7	-	24.0	-	NPAT and EPS forecasts are statutory. Underlying operating PBT forecast is $240.5m.
27/08/2026	BLX	$1.68	FY	Leo Armati	$2.05	Buy	-	86.1	-	28.6	-	12.6	4.1	2.9	Expecting rate-hike led impact to retail segment (BPe -4.7%), Trade segment growth (BPe +11.4%), and inflation-led GM pressure (BPe 68.6% vs. 69.1% in pcp)
27/08/2026	BUB	$0.09	FY	Jonathan Snape	$0.14	Buy (Spec)	-	-0.4	-	-3.4	-	-0.4	-	-	FY26e revenue guidance of $120-125m and EBITDA OF -$2M TO +$2M
27/08/2026*	CCV	$0.33	FY	Leo Armati	$0.34	Buy	-	67.7	-	24.9	-	3.6	1.0	1.0	Cashies loan book growth (BPe 38.9%), Store pipeline outlook (BPe 17 per annum), Retail comp sales in Aus/UK (BPe Aus UK 8%)
27/08/2026	CNI	$1.47	FY	Andy MacFarlane	$2.00	Hold	89.3	189.1	54.6	113.1	6.6	13.6	5.2	10.4	FUM target of +$1bn acquisitions in FY26 (ex Debt) for organic on track, but questions marks on CSPOF raising success and sponsor issues in Bass Capital business
27/08/2026	GDG	$4.02	FY	Hayden Nicholson	$6.20	Buy	-	43.7	-	42.1	-	10.6	-	1.0	Evidentia pre-reported FUM growth of +37%, with average period FUM +16% above opening.

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

BELL POTTER REPORTING SEASON CALENDAR AUGUST 2026

Report Date (* Estimate)	Code	Price	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m) HY26	EBITDA Forecast ($m) FY26	Adjusted NPAT Forecast ($m) HY26	Adjusted NPAT Forecast ($m) FY26	Adjusted EPS Forecast (cents) HY26	Adjusted EPS Forecast (cents) FY26	DPS Forecast (cents) Interim HY26 Dividend	DPS Forecast (cents) Final FY26 Dividend	Comments
27/08/2026	IRI	$0.30	FY	Chris Savage	$0.38	Buy	-	-3.1	-	-0.1	-	-0.1	-	-	Forecasts are statutory.
27/08/2026	JIN	$7.31	FY	Baxter Kirk	$7.10	Hold	-	83.2	-	40.7	-	64.5	12.0	24.0	-
27/08/2026	MIN	$57.73	FY	James Williamson	$75.00	Buy	-	2,502.9	-	772.0	-	391.4	-	65.1	See potential for dividend with balance sheet targets set out in the capital allocation framework now within range.
27/08/2026	MYG	$2.12	FY	Joseph House	$3.20	Buy	-	15.1	-	9.0	-	8.2	2.0	5.2	Expecting outlook commentary to be bullish given record WIH entering FY27 and generally positive indicators in key construction markets.
27/08/2026*	NEU	$18.59	HY	Thomas Wakim	$23.50	Buy	-6.3	-	-0.3	-	-0.3	-	-	-	Royalty revenue will be informed by Acadia's Q2 result on 5th August.
27/08/2026*	PDN	$9.41	FY	James Williamson	$14.80	Buy	-	71.1	-	5.1	-	0.6	-	-	All figures in US$.
27/08/2026*	PGC	$0.13	FY	John Hester	$0.17	Hold	-	95.1	-	22.2	-	1.3	-	-	PGC had a poor year in FY26. Looking forward to a substantial turnaround in FY27.
27/08/2026	SIG	$2.97	FY	John Hester	$3.00	Hold	-	1,165.8	-	746.1	-	6.5	2.0	4.5	Expecting another very strong result for top line growth
27/08/2026	SIQ	$12.99	HY	Hayden Nicholson	$11.50	Buy	72.6	-	7.0	-	32.6	-	21.7	-	1Q26 average monthly revenue growth of +8%, novated leasing settlements up +7%, and order growth of +22%. Our estimates anticipate an acceleration to +9% revenue growth.
27/08/2026*	SLD	$0.43	FY	Thomas Wakim	$1.60	Buy (Spec)	-	-108.4	-	-119.0	-	-0.4	-	-	Revenue pre-released at quarterly. Outside of Prospectus forecasts, guidance only given for GM, which is >46%.
27/08/2026	SNS	$0.03	FY	Chris Savage	$0.08	Buy	-	2.1	-	0.9	-	0.1	-	-	EBITDA forecast is underlying. NPAT and EPS forecasts are statutory.

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Report Date (* Estimate)	Code	Price	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m)		Adjusted NPAT Forecast ($m)		Adjusted EPS Forecast (cents)		DPS Forecast (cents)		Comments
							HY26	FY26	HY26	FY26	HY26	FY26	Interim HY26 Dividend	Final FY26 Dividend	
27/08/2026*	SNT	$0.03	FY	Thomas Wakim	$0.06	Buy (Spec)	-	-10.5	-	-10.6	-	-0.5	-	-	Pre-revenue, clinical-stage biotech. $13.5m cash balance at 30-June-2026.
27/08/2026	SNZ	$7.00	HY	Andy MacFarlane	$14.40	Buy	115.2	279.8	101.9	236.5	42.2	97.8	12.5	25.0	CY26 guidance for 750-850 new homes build rate under ORA across Aus and NZ (vs. 693 in CY25). Market focused on net debt position.
27/08/2026*	TRJ	$0.21	FY	Martyn Jacobs	$0.75	Buy	-	14.0	-	2.6	-	1.7	-	-	Pre-released downgraded guidance. Macro risks impacting growth. Further downside risk relative to BPe EBITDA growth of c.38%
28/08/2026*	ASB	$3.65	FY	Baxter Kirk	$4.10	Hold	-	191.3	-	84.7	-	15.8	-	-	Estimates including substantial contribution from the MMF3 accounting which should be considers as non-underlying
28/08/2026*	AUC	$0.84	FY	James Williamson	$1.60	Buy (Spec)	-	-12.0	-	-12.9	-	-2.4	-	-	Project development company. Financial result not relevant to investment thesis.
28/08/2026	AV1	$0.08	FY	Chris Savage	$0.16	Buy	-	-4.1	-	-4.3	-	-0.5	-	-	Forecasts are statutory.
28/08/2026*	AVR	$11.29	HY	John Hester	$13.00	Buy	-56.6	-	-57.2	-	-59.0	-	-	-	Update on progress of PARADIGM study for DURAVR
28/08/2026*	AYA	$4.05	FY	Martyn Jacobs	$6.10	Buy	-	-23.7	-	-24.4	-	-15.4	-	-	First revenues in 2H26, with potential for downside risk v BPe $2.9m. Market is looking for confirmation that all foundation customers have been onboarded and generating Plaque revenue. Update on submission of FFR-CT module for FDA approval.
28/08/2026*	BOE	$1.22	FY	James Williamson	$1.80	Buy	-	28.5	-	11.5	-	2.8	-	-	More clarity on Honeymoon Life-of-Mine plan by end August 2026.
28/08/2026	CYC	$0.56	HY	John Hester	$1.00	Buy	-8.8	-	-9.0	-	-7.2	-	-	-	Update on progress of technegas roll out in the US, cash burn update

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Report Date (* Estimate)	Code	Price	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m)		Adjusted NPAT Forecast ($m)		Adjusted EPS Forecast (cents)		DPS Forecast (cents)		Comments
							HY26	FY26	HY26	FY26	HY26	FY26	Interim HY26 Dividend	Final FY26 Dividend	
28/08/2026	EMV	$1.60	FY	Martyn Jacobs	$3.15	Buy (Spec)	-	-8.5	-	-9.1	-	-9.8	-	-	Pre-revenue company with primary focus on progress with pivotal emu trial and Frist Responder feasibility studies
28/08/2026	HVN	$4.92	FY	Chami Ratnapala	$6.00	Buy	-	1,093.8	-	443.1	-	35.5	14.5	29.8	One-off expense of $35-38m (as per BPe) to be recognised in FY26 financials
28/08/2026*	IMM	$0.05	FY	Thomas Wakim	$0.07	Hold (Spec)	-	-55.9	-	-55.4	-	-3.8	-	-	Pre-revenue, clinical-stage biotech. $69m cash balance at 30-June-2026.
28/08/2026	IPD	$0.01	FY	Martyn Jacobs	$0.02	Buy (Spec)	-	-18.2	-	-23.5	-	-0.7	-	-	4Q26 result is more important in understanding performance. Looking for Sozo volume >40 units for June qtr.
28/08/2026	ITS	$0.26	FY	Chris Savage	$0.58	Buy	-	2.7	-	-4.6	-	-2.4	-	-	EBITDA forecast is underlying. NPAT and EPS forecasts are statutory.
28/08/2026	LDX	$0.11	FY	Martyn Jacobs	$0.25	Buy	-	-7.3	-	-11.5	-	-1.2	-	-	Early US rollout data will be limited. Focus will be on outlook for US rollout ahead of US flu season which should be peak for FebriDx ordering cycle. Looking fo rfurther Urgent Care sign-ups.
28/08/2026	MMS	$19.63	FY	Hayden Nicholson	$19.90	Buy	-	178.6	-	106.8	-	153.4	-	65.0	Outlook indicates higher 2H profits, driven by broad-based customer growth, with 3Q26 new vehicle lease growth of +7%.
28/08/2026*	PYC	$1.82	FY	Thomas Wakim	$2.30	Buy (Spec)	-	-59.5	-	-52.2	-	-5.3	-	-	Pre-revenue, clinical-stage biotech. $670m cash balance at 30-June-2026.
31/08/2026	4DX	$3.96	FY	John Hester	$6.00	Buy (Spec)	-	-32.0	-	-38.3	-	-6.4	-	-	Focus on outlook statements for revenue growth
31/08/2026*	CU6	$2.36	FY	John Hester	$6.50	Buy (Spec)	-	-98.0	-	-92.0	-	-24.9	-	-	Potential for an update on progress of various clinical trials
31/08/2026*	CVL	$1.70	FY	Baxter Kirk	$1.90	Buy	-	98.9	-	47.8	-	9.4	2.5	4.3	-

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Report Date (* Estimate)	Code	Price	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m) HY26	EBITDA Forecast ($m) FY26	Adjusted NPAT Forecast ($m) HY26	Adjusted NPAT Forecast ($m) FY26	Adjusted EPS Forecast (cents) HY26	Adjusted EPS Forecast (cents) FY26	DPS Forecast (cents) Interim HY26 Dividend	DPS Forecast (cents) Final FY26 Dividend	Comments
31/08/2026*	EIQ	$1.33	FY	John Hester	$1.75	Hold (Spec)	-	-9.6	-	-10.2	-	-1.6	-	-	We expect nil revenues from operations, commercialisation update will be relevant
31/08/2026*	FLC	$0.07	HY	Ritesh Varma	$0.11	Buy (Spec)	1.8	-	0.2	-	0.0	-	-	-	Look for continued SPS + RR revenue growth.
31/08/2026	IMU	$0.08	FY	John Hester	$0.25	Buy (Spec)	-	-57.3	-	-59.9	-	-14.4	-	-	-
31/08/2026	LTR	$0.99	FY	Stuart Howe	$1.90	Buy	-	222.0	-	34.0	-	1.2	-	-	FY26 result to reflect ramp-up year & transition from open pit to UG mining. Key catalyst: Expansion study & FID by late Sep'26.
31/08/2026	MSB	$2.03	FY	John Hester	$4.45	Buy	-	-25.2	-	-67.5	-	-5.3	-	-	Company may provide further granularity on commercialisation progress for Ryoncil
31/08/2026*	PAR	$0.18	FY	John Hester	$0.42	Buy (Spec)	-	-49.0	-	-49.0	-	-8.5	-	-	-
31/08/2026*	RAD	$0.01	FY	John Hester	$0.06	Buy (Spec)	-	-46.1	-	-43.1	-	-1.3	-	-	RAD is expected to complete a partering deal in 2HCY26 for RAD101
31/08/2026	RIV	$1.42	HY	Jonathan Snape	$1.61	Buy	-	13.1	-	8.4	-	5.3	3.7	7.4	No guidance. Lease levels are higher in 2H26e
31/8/2026*	RMY	$0.03	FY	Michael Ardrey	$0.07	Buy (Spec)	-	0.4	-	-0.7	-	-0.1	-	-	Revenue pre-reported, grew 10% to $22.7m; top-down brokerage deal momentum strong, but yet to convert into meaningful revenue
01/09/2026*	A4N	$0.49	FY	Stuart Howe	$1.50	Buy (Spec)	-	21.0	-	-69.0	-	-4.8	-	-	Project development company, result not relevant to investment view. Catalyst: Stage 2 development updates & first debt drawdown (expected Q4 '26).
01/09/2026*	BIO	$0.28	FY	Martyn Jacobs	$0.75	Buy	-	2.9	-	2.4	-	1.1	-	-	Headline sales pre-released did not meet expectations. Focus will be on whether margins can reach double-digits. BPe at 12%

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Report Date (* Estimate)	Code	Price	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m) HY26	EBITDA Forecast ($m) FY26	Adjusted NPAT Forecast ($m) HY26	Adjusted NPAT Forecast ($m) FY26	Adjusted EPS Forecast (cents) HY26	Adjusted EPS Forecast (cents) FY26	DPS Forecast (cents) Interim HY26 Dividend	DPS Forecast (cents) Final FY26 Dividend	Comments
01/09/2026*	TTT	$0.18	FY	Stuart Howe	$0.46	Buy (Spec)	-	-22.0	-	-24.0	-	-1.6	-	-	Project development company, result not relevant to investment view. Catalyst: Commercial agreement & market updates.
04/09/2026*	CYL	$5.76	FY	Todd Lewis	$13.25	Buy	225.3	370.3	153.6	208.9	58.9	80.2	-	-	Production and costs meeting/ beating guidance. Look for FY27 guidance and strategy in 1QFY27
07/09/2026*	CMM	$12.79	FY	David Coates	$17.80	Buy	-	525.4	-	331.6	-	76.9	5.0	9.0	Fully funded to build new mine start 2HFY27
08/09/2026*	WTM	$0.48	HY	David Coates	$1.05	Buy (Spec)	-	-20.4	-	-21.4	-	-5.9	-	-	Exploration / development company, cash $58m
11/09/2026	VUL	$2.62	HY	Stuart Howe	$4.50	Buy (Spec)	-	-	-	-	-	-	-	-	Project development company, result not relevant to investment view. Catalyst: Project development updates; lithium market news.
14/09/2026*	CRD	$0.59	HY	Stuart Howe	$1.05	Buy (Spec)	-	-	-	-	-	-	-	-	Project development company, result not relevant to investment view. Catalyst: Mako-PT Nations farm down completion, expected in current quarter.
15/09/2026	NHC	$5.15	FY	James Williamson	$5.00	Hold	-	490.7	-	151.4	-	18.0	-	10.0	Upside risk to earnings estimates with potential for a strong 4Q (4Q quarterly report scheduled 17-Aug-26; July year-end).
18/09/2026*	SKY	$0.24	FY	James Williamson	$0.30	Buy (Spec)	-	-4.2	-	-3.8	-	-0.4	-	-	Project development company. Financial result not relevant to investment thesis.
23/09/2026*	LNQ	$0.34	FY	David Coates	$0.90	Buy	-	-4.2	-	-4.4	-	-2.2	-	-	Exploration / development company, cash $16m
23/09/2026*	WC8	$0.33	FY	James Williamson	$1.00	Buy (Spec)	-	-10.7	-	-9.5	-	-0.7	-	-	Project development company. Financial result not relevant to investment thesis.
24/09/2026*	PMV	$13.47	FY	Chami Ratnapala	$26.50	Buy	-	260.4	-	156.2	-	98.2	45.0	79.7	Guidance Retail EBIT (Pre-AASB 16) for FY26 at $183m (BPe at guidance)

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Report Date (* Estimate)	Code	Price	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m) HY26	EBITDA Forecast ($m) FY26	Adjusted NPAT Forecast ($m) HY26	Adjusted NPAT Forecast ($m) FY26	Adjusted EPS Forecast (cents) HY26	Adjusted EPS Forecast (cents) FY26	DPS Forecast (cents) Interim HY26 Dividend	DPS Forecast (cents) Final FY26 Dividend	Comments
25/09/2026	CHN	$1.15	FY	David Coates	$4.00	Buy (Spec)	-	-	-	-	-	-	-	-	Exploration / development company, cash $51m
25/09/2026*	COI	$0.09	FY	Stuart Howe	$0.14	Buy (Spec)	-	-3.0	-	-4.0	-	-0.3	-	-	Project development company, result not relevant to investment view. Catalyst: Completing Mahalo acquisition and FEED; securing project partner.
25/09/2026*	DLI	$0.16	FY	James Williamson	$0.41	Buy (Spec)	-	-8.2	-	-7.2	-	-1.0	-	-	Project development company. Financial result not relevant to investment thesis.
25/09/2026*	MI6	$0.62	FY	David Coates	$1.40	Buy	-	-12.9	-	-12.2	-	-0.6	-	-	Exploration / development company, cash $211m
28/09/2026*	OMA	$0.51	FY	Stuart Howe	$1.40	Buy (Spec)	-	-10.0	-	5.0	-	1.2	-	-	Project development company, result not relevant to investment view. Catalyst: Taroom Trough appraisal activity.
28/09/2026*	PNR	$2.02	FY	David Coates	$2.25	Hold	-	316.7	-	173.1	-	44.1	-	-	Downside risk on higher costs from 2HFY26
28/09/2026*	STX	$0.10	FY	Stuart Howe	$0.16	Buy (Spec)	-	17.0	-	-35.0	-	-1.0	-	-	Finanial result based on Walyering production only; key to company value is South Erregulla power plant (Commissioning Oct26) and pre-FID West Erregulla JV.
28/09/2026*	WA1	$11.13	FY	Todd Lewis	$27.20	Buy (Spec)	-14.7	-18.9	-12.6	-14.9	-0.2	-0.2	-	-	Exploration / development company, cash $124m
29/09/2026*	AGE	$0.05	FY	James Williamson	$0.08	Buy (Spec)	-	-11.2	-	-10.7	-	-0.2	-	-	Project development company. Financial result not relevant to investment thesis.
29/09/2026*	ARR	$0.34	FY	Todd Lewis	$0.65	Buy (Spec)	-3.0	-6.0	-2.5	-5.3	-0.4	-0.9	-	-	Exploration / development company, cash $18.6m
29/09/2026*	DEV	$0.24	FY	Stuart Howe	$0.41	Buy (Spec)	-	-11.0	-	-10.0	-	-1.8	-	-	Project development company, result not relevant to investment view. Catalyst: Exploration results.

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Report Date (* Estimate)	Code	Price	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m) HY26	EBITDA Forecast ($m) FY26	Adjusted NPAT Forecast ($m) HY26	Adjusted NPAT Forecast ($m) FY26	Adjusted EPS Forecast (cents) HY26	Adjusted EPS Forecast (cents) FY26	DPS Forecast (cents) Interim HY26 Dividend	DPS Forecast (cents) Final FY26 Dividend	Comments
29/09/2026*	DYL	$1.33	FY	James Williamson	$1.90	Hold (Spec)	-	-15.3	-	-9.2	-	-0.9	-	-	Project development company. Financial result not relevant to investment thesis.
29/09/2026*	SM1	$0.30	FY	Jonathan Snape	$0.39	Hold	-	18.0	-	-66.3	-	-11.0	-	-	-
29/09/2026*	SMI	$0.50	FY	David Coates	$1.70	Buy (Spec)	-	-7.2	-	-6.8	-	-0.8	-	-	Exploration / development company, cash $188m
29/09/2026*	VMM	$3.30	FY	Todd Lewis	$4.30	Buy (Spec)	-1.5	-3.0	-0.5	-2.0	-1.1	-3.9	-	-	Exploration / development company, cash $20.5m
30/09/2026	FRS	$0.33	FY	Todd Lewis	$1.15	Buy (Spec)	16.8	16.8	13.6	11.2	1.9	1.9	-	-	Development/ near term producing company. Recently acquired Edna May. Producer in 2027.
30/09/2026*	IPX	$3.01	FY	Stuart Howe	$5.60	Buy (Spec)	-	-41.0	-	-45.0	-	-19.3	-	-	Project development company, result not relevant to investment view. Catalyst: Commercial agreement & market updates.
07/10/2026*	AUE	$0.48	FY	David Coates	$1.50	Buy (Spec)	-	-13.0	-	-15.0	-	-4.3	-	-	Exploration / development company, cash $55m
20/10/2026*	FAL	$0.42	FY	Todd Lewis	$1.10	Buy (Spec)	-0.6	-4.4	-0.3	-4.1	-1.9	-1.9	-	-	Exploration / development company, cash $15.4m
12/11/2026	ALL	$64.35	FY	Baxter Kirk	$61.00	Buy	-	2,190.0	-	1,547.0	-	255.1	50.0	99.0	September year end
12/11/2026	GNC	$5.66	FY	Jonathan Snape	$5.90	Buy	-	228.6	-	38.4	-	17.5	14.0	24.0	-
16/11/2026	ELD	$5.64	FY	Jonathan Snape	$6.45	Buy	-	285.9	-	104.5	-	48.9	18.0	36.0	-

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Report Date (* Estimate)	Code	Price	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m)		Adjusted NPAT Forecast ($m)		Adjusted EPS Forecast (cents)		DPS Forecast (cents)		Comments
							HY26	FY26	HY26	FY26	HY26	FY26	Interim HY26 Dividend	Final FY26 Dividend	
24/11/2026*	GTK	$3.08	FY	Michael Ardrey	$5.60	Buy	-	15.4	-	6.9	-	6.2	-	-	-
25/11/2026*	SHV	$4.19	FY	Jonathan Snape	$5.30	Buy	-	113.9	-	49.3	-	34.9	3.5	10.0	-
27/11/2026*	ATX	$0.14	HY	Thomas Wakim	$0.42	Buy (Spec)	-5.8	-	-5.8	-	-1.1	-	-	-	Pre-revenue, clinical-stage biotech. $24m cash balance at 30-June-2026.
26/02/2027	6KA	$0.67	FY	Stuart Howe	$1.50	Buy (Spec)	-	-7.0	-	-12.0	-	-4.6	-	-	Project development company, result not relevant to investment view. Catalyst: Commercial agreement & market updates.
TBC	AAL	$0.27	FY	Joseph House	$0.27	Hold	-	26.6	-	7.8	-	2.7	-	-	Focus will be on the outlook for FCF improvement and pathway to dividend reinstatement.
September	DVP	$4.76	FY	Joseph House	$6.50	Buy	-	61.6	-	28.1	-	8.2	-	-	Does not report in August. Annual report to be published in September.
TBA	OCC	$0.71	FY	Brenton Anderson	$1.19	Buy (Spec)	-	-12.3	-	-11.0	-	-4.2	-	-	Company doesn't provide guidance. $44.1m funds available at 30-June-2026
TBA	PPS	$0.73	FY	Hayden Nicholson	$1.20	Buy	-	31.9	-	18.1	-	3.8	-	1.4	Pre-reported custodial FUA growth of +11%, with average period FUA +9% higher
N/A	TNE	$31.02	N/A	Chris Savage	$34.25	Hold	-	-	-	-	-	-	-	-	-

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

REPORTING CALENDAR ALPHABETICAL ORDER.

Code	Price	Report Date (* *Estimate)*	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m)		Adjusted NPAT Forecast ($m)		Adjusted EPS Forecast (cents)		DPS Forecast (cents)		Comments
							HY26	FY26	HY26	FY26	HY26	FY26	Interim HY26 Dividend	Final FY26 Dividend	
360	$25.56	11/08/2026	HY	Chris Savage	$35.00	Buy	42.8	-	40.1	-	15.1	-	-	-	Forecasts are in USD/USC. EBITDA forecast is adjusted.
4DX	$3.96	31/08/2026	FY	John Hester	$6.00	Buy (Spec)	-	-32.0	-	-38.3	-	-6.4	-	-	Focus on outlook statements for revenue growth
6KA	$0.67	26/02/2027	FY	Stuart Howe	$1.50	Buy (Spec)	-	-7.0	-	-12.0	-	-4.6	-	-	Project development company, result not relevant to investment view. Catalyst: Commercial agreement & market updates.
A2M	$6.86	17/08/2026	FY	Jonathan Snape	$6.90	Hold	-	234.9	-	168.8	-	23.2	8.2	60.2	FY26e Revenue guidance of NZ$1.93-2.02Bn, with an EBITDA margin of 14.0-14.5%
A4N	$0.49	01/09/2026*	FY	Stuart Howe	$1.50	Buy (Spec)	-	21.0	-	-69.0	-	-4.8	-	-	Project development company, result not relevant to investment view. Catalyst: Stage 2 development updates & first debt drawdown (expected Q4 '26).
AAL	$0.27	TBC	FY	Joseph House	$0.27	Hold	-	26.6	-	7.8	-	2.7	-	-	Focus will be on the outlook for FCF improvement and pathway to dividend reinstatement.
ABY	$0.25	24/08/2026	FY	Leo Armati	$0.39	Hold	-	4.0	-	-0.8	-	-0.0	-	-	FY26 guidance: Underlying EBITDA of $4.0m and 2H26 GM of 34.5%. To look for: NDC progress and FY27 commentary
ADH	$1.39	24/08/2026	FY	Chami Ratnapala	$1.45	Hold	-	68.3	-	33.8	-	19.0	5.5	9.9	Guidance of $53.5-55.5m EBIT (Pre-AASB 16) for FY26
AEL	$1.51	18/08/2026	FY	Stuart Howe	$2.50	Buy	-	196.8	-	47.2	-	17.5	-	-	East Coast Supply Project exploration success and development updates the key catalyst. Juliet exploration results due mid-Aug'26. FY26 earnings less relevant.

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Code	Price	Report Date (* Estimate)	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m) HY26	EBITDA Forecast ($m) FY26	Adjusted NPAT Forecast ($m) HY26	Adjusted NPAT Forecast ($m) FY26	Adjusted EPS Forecast (cents) HY26	Adjusted EPS Forecast (cents) FY26	DPS Forecast (cents) Interim HY26 Dividend	DPS Forecast (cents) Final FY26 Dividend	Comments
AGE	$0.05	29/09/2026*	FY	James Williamson	$0.08	Buy (Spec)	-	-11.2	-	-10.7	-	-0.2	-	-	Project development company. Financial result not relevant to investment thesis.
AHC	$0.23	26/08/2026*	FY	Martyn Jacobs	$0.45	Buy	-	14.3	-	9.0	-	2.4	-	-	Guidance previously downgraded reflecting sectoral and macro events. Market will be looking for whether headwids have eased.
AHL	$1.16	18/08/2026	FY	Chris Savage	$1.35	Hold	-	19.4	-	5.9	-	7.3	-	2.2	EBITDA forecast is underlying. NPAT and EPS forecasts are statutory.
AL3	$0.12	25/08/2026*	FY	Stuart Howe	$0.35	Buy (Spec)	-	-2.0	-	-3.0	-	-0.5	-	-	Project development company, result not relevant to investment view. Catalyst: Commercial agreement & market updates.
ALC	$0.09	26/08/2026*	FY	Thomas Wakim	$0.15	Buy	-	5.8	-	1.0	-	0.1	-	-	Revenue pre-released at quarterly. EBITDA guidance is >$5m.
ALK	$1.31	20/08/2026	FY	David Coates	$2.10	Buy	-	473.0	-	238.4	-	17.4	-	-	First year of merger with Mandalay
ALL	$64.35	12/11/2026	FY	Baxter Kirk	$61.00	Buy	-	2,190.0	-	1,547.0	-	255.1	50.0	99.0	September year end
AMA	$0.46	21/08/2026	FY	Chris Savage	$1.00	Buy	-	68.4	-	5.8	-	1.2	-	-	EBITDA forecast is normalised pre AASB 16. NPAT and EPS forecasts are statutory post AASB 16.
APE	$23.85	27/08/2026	HY	Chris Savage	$28.00	Buy	431.2	-	128.1	-	44.7	-	24.0	-	NPAT and EPS forecasts are statutory. Underlying operating PBT forecast is $240.5m.
APZ	$5.17	18/08/2026	FY	Andy MacFarlane	$6.50	Buy	26.3	54.2	24.3	48.2	10.7	21.2	5.5	11.0	FY26 guidance is for 21.5c pre-tax EPS; Key markets in WA and SA continue to perform well; looking for margin expansion and update on BTR book
AR1	$0.06	09/08/2026*	HY	David Coates	$0.17	Buy	-	$57m	-	41.0	-	1.6	-	-	Transitioning to production, cash $83m

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Code	Price	Report Date *(* Estimate)*	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m) HY26	EBITDA Forecast ($m) FY26	Adjusted NPAT Forecast ($m) HY26	Adjusted NPAT Forecast ($m) FY26	Adjusted EPS Forecast (cents) HY26	Adjusted EPS Forecast (cents) FY26	DPS Forecast (cents) Interim HY26 Dividend	DPS Forecast (cents) Final FY26 Dividend	Comments
ARR	$0.34	29/09/2026*	FY	Todd Lewis	$0.65	Buy (Spec)	-3.0	-6.0	-2.5	-5.3	-0.4	-0.9	-	-	Exploration / development company, cash $18.6m
ASB	$3.65	28/08/2026*	FY	Baxter Kirk	$4.10	Hold	-	191.3	-	84.7	-	15.8	-	-	Estimates including substantial contribution from the MMF3 accounting which should be considers as non-underlying
ATX	$0.14	27/11/2026*	HY	Thomas Wakim	$0.42	Buy (Spec)	-5.8	-	-5.8	-	-1.1	-	-	-	Pre-revenue, clinical-stage biotech. $24m cash balance at 30-June-2026.
AUC	$0.84	28/08/2026*	FY	James Williamson	$1.60	Buy (Spec)	-	-12.0	-	-12.9	-	-2.4	-	-	Project development company. Financial result not relevant to investment thesis.
AUE	$0.48	07/10/2026*	FY	David Coates	$1.50	Buy (Spec)	-	-13.0	-	-15.0	-	-4.3	-	-	Exploration / development company, cash $55m
AV1	$0.08	28/08/2026	FY	Chris Savage	$0.16	Buy	-	-4.1	-	-4.3	-	-0.5	-	-	Forecasts are statutory.
AVH	$1.29	07/08/2026*	HY	John Hester	$1.20	Hold (Spec)	-15.4	-	-19.9	-	-58.0	-	-	-	Expecting strong recover in revenues following resolution on MACS reimbursement
AVR	$11.29	28/08/2026*	HY	John Hester	$13.00	Buy	-56.6	-	-57.2	-	-59.0	-	-	-	Update on progress of PARADIGM study for DURAVR
AX1	$0.71	21/08/2026	FY	Chami Ratnapala	$0.80	Hold	-	281.1	-	34.4	-	5.7	3.3	3.9	Guidance of EBIT $79.5-84.5m for FY26
AYA	$4.05	28/08/2026*	FY	Martyn Jacobs	$6.10	Buy	-	-23.7	-	-24.4	-	-15.4	-	-	First revenues in 2H26, with potential for downside risk v BPe $2.9m. Market is looking for confirmation that all foundation customers have been onboarded and generating Plaque revenue. Update on submission of FFR-CT module for FDA approval.

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Code	Price	Report Date (* Estimate)	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m) HY26	EBITDA Forecast ($m) FY26	Adjusted NPAT Forecast ($m) HY26	Adjusted NPAT Forecast ($m) FY26	Adjusted EPS Forecast (cents) HY26	Adjusted EPS Forecast (cents) FY26	DPS Forecast (cents) Interim HY26 Dividend	DPS Forecast (cents) Final FY26 Dividend	Comments
BGA	$6.14	20/08/2026	FY	Jonathan Snape	$7.75	Buy	-	224.7	-	69.9	-	22.9	7.0	14.0	FY26e EBITDA guidance of $222-227m
BIO	$0.28	01/09/2026*	FY	Martyn Jacobs	$0.75	Buy	-	2.9	-	2.4	-	1.1	-	-	Headline sales pre-released did not meet expectations. Focus will be on whether margins can reach double-digits. BPe at 12%
BLX	$1.68	27/08/2026	FY	Leo Armati	$2.05	Buy	-	86.1	-	28.6	-	12.6	4.1	2.9	Expecting rate-hike led impact to retail segment (BPe -4.7%), Trade segment growth (BPe +11.4%), and inflation-led GM pressure (BPe 68.6% vs. 69.1% in pcp)
BOE	$1.22	28/08/2026*	FY	James Williamson	$1.80	Buy	-	28.5	-	11.5	-	2.8	-	-	More clarity on Honeymoon Life-of-Mine plan by end August 2026.
BPT	$0.91	6/08/2026	FY	Stuart Howe	$0.95	Hold	-	937.3	-	379.6	-	16.6	1.0	2.0	Downside risk to DPS (capital management review underway) and to FY27 guidance to be issued with result (BP est. 21.4mmboe).
BUB	$0.09	27/08/2026	FY	Jonathan Snape	$0.14	Buy (Spec)	-	-0.4	-	-3.4	-	-0.4	-	-	FY26e revenue guidance of $120-125m and EBITDA OF -$2M TO +$2M
C79	$5.96	11/08/2026	FY	Joseph House	$7.80	Buy	-	29.4	-	2.5	-	2.1	-	-	FY27 revenue guidance will be highly anticipated to affirm deployment expectations. Restoration of confidence in the deployment outlook is key for C79.
CAR	$25.98	10/08/2026	FY	Michael Ardrey	$34.60	Buy	-	709.8	-	406.1	-	107.4	42.5	80.6	Consensus adj. NPAT (cc) growth currently below CAR guidance; positive result ahead of market expectations could meet large short position (11.5%)
CCL	$5.06	20/08/2026	FY	Hayden Nicholson	$5.80	Buy	-	76.1	-	44.0	-	22.6	-	5.3	1H26 NPAT is expected to be 55% of FY26, implying $44m guidance based on high-single-digit volume growth.
CCV	$0.33	27/08/2026*	FY	Leo Armati	$0.34	Buy	-	67.7	-	24.9	-	3.6	1.0	1.0	Cashies loan book growth (BPe 38.9%), Store pipeline outlook (BPe 17 per annum), Retail comp sales in Aus/UK (BPe Aus UK 8%)

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Code	Price	Report Date (* Estimate)	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m)		Adjusted NPAT Forecast ($m)		Adjusted EPS Forecast (cents)		DPS Forecast (cents)		Comments
							HY26	FY26	HY26	FY26	HY26	FY26	Interim HY26 Dividend	Final FY26 Dividend	
CDA	$40.08	20/08/2026*	FY	Baxter Kirk	$41.30	Hold	-	275.3	-	169.9	-	93.6	19.5	46.8	-
CGS	$2.51	18/08/2026	FY	Thomas Wakim	$3.70	Buy	-	17.3	-	10.9	-	6.3	-	2.0	All figures in USD except DPS. Only specific FY26 guidance is 2H26 GM 56-59%.
CHN	$1.15	25/09/2026	FY	David Coates	$4.00	Buy (Spec)	-	-	-	-	-	-	-	-	Exploration / development company, cash $51m
CIA	$3.31	30/07/2026*	HY	Stuart Howe	$3.40	Hold	-	-	-	-	-	-	-	-	Mar YE. Q1 FY27 reported -C$42m adjusted net loss. Next release dates: AGM 26 Aug; Q2 FY27 29 Oct.
CIP	$3.01	11/08/2026	FY	Andy MacFarlane	$3.60	Buy	88.9	180.1	57.3	115.7	9.1	18.5	8.4	16.8	FY26 guidance for FFO / share of 18.2-18.5c (increased bottom end at 1Q26) and DPS of 16.8c
CMM	$12.79	07/09/2026*	FY	David Coates	$17.80	Buy	-	525.4	-	331.6	-	76.9	5.0	9.0	Fully funded to build new mine start 2HFY27
CNI	$1.47	27/08/2026	FY	Andy MacFarlane	$2.00	Hold	89.3	189.1	54.6	113.1	6.6	13.6	5.2	10.4	FUM target of +$1bn acquisitions in FY26 (ex Debt) for organic on track, but questions marks on CSPOF raising success and sponsor issues in Bass Capital business
COF	$0.91	4/08/2026	FY	Michael Armstrong	$0.95	Hold	58.1	115.5	33.4	67.0	5.6	11.2	5.1	10.1	Looking for commentary on office lease-up, particularly within the challenged Docklands and St Leonards markets. Potential for COF to lower its dividend in FY27 as currently it is not cash earnings covered.
COG	$1.38	26/08/2026	FY	Hayden Nicholson	$2.10	Buy	-	48.3	-	29.9	-	14.4	-	3.5	EBITDA and NPAT estimates are ex-minorities.
COI	$0.09	25/09/2026*	FY	Stuart Howe	$0.14	Buy (Spec)	-	-3.0	-	-4.0	-	-0.3	-	-	Project development company, result not relevant to investment view. Catalyst: Completing Mahalo acquisition and FEED; securing project partner.

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Code	Price	Report Date (* Estimate)	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m) HY26	EBITDA Forecast ($m) FY26	Adjusted NPAT Forecast ($m) HY26	Adjusted NPAT Forecast ($m) FY26	Adjusted EPS Forecast (cents) HY26	Adjusted EPS Forecast (cents) FY26	DPS Forecast (cents) Interim HY26 Dividend	DPS Forecast (cents) Final FY26 Dividend	Comments
COL	$24.27	25/08/2026	FY	Jonathan Snape	$22.80	Hold	-	4,220.5	-	1,194.8	-	89.0	41.0	75.0	No guidance, 4Q revenue expected to be bolstered by supplier price increase requests
CRD	$0.59	14/09/2026*	HY	Stuart Howe	$1.05	Buy (Spec)	-	-	-	-	-	-	-	-	Project development company, result not relevant to investment view. Catalyst: Mako-PT Nations farm down completion, expected in current quarter.
CRN	$0.18	11/08/2026	HY	James Williamson	$0.17	Sell (Spec)	-	-86.3	-	-226.8	-	-13.5	-	-	All figures in US$.
CSL	$124.30	18/08/2026	FY	Thomas Wakim	$120.00	Hold	-	5,246.0	-	3,104.0	-	638.3	130.0	160.0	All figures in USD. BPe in line with FY26 guidance of NPATA $3.1b. We forecast further earnings decline (-7%) in FY27 vs consensus at +1%.
CU6	$2.36	31/08/2026*	FY	John Hester	$6.50	Buy (Spec)	-	-98.0	-	-92.0	-	-24.9	-	-	Potential for an update on progress of various clinical trials
CUV	$9.16	26/08/2026*	FY	Thomas Wakim	$17.00	Buy	-	42.2	-	36.2	-	71.8	-	5.0	Company doesn't provide guidance.
CVL	$1.70	31/08/2026*	FY	Baxter Kirk	$1.90	Buy	-	98.9	-	47.8	-	9.4	2.5	4.3	-
CWP	$6.85	25/08/2026	FY	Michael Armstrong	$9.30	Buy	62.2	99.4	39.6	63.3	47.9	76.7	14.0	38.0	Our bottom up analysis has CWP recording 1,100 settlements in FY26, growing to c. 1,183 in FY27. Interested in equiry/sales levels following May '26 budget changes and forecasts for FY27 sales
CYC	$0.56	28/08/2026	HY	John Hester	$1.00	Buy	-8.8	-	-9.0	-	-7.2	-	-	-	Update on progress of technegas roll out in the US, cash burn update
CYL	$5.76	04/09/2026*	FY	Todd Lewis	$13.25	Buy	225.3	370.3	153.6	208.9	58.9	80.2	-	-	Production and costs meeting/ beating guidance. Look for FY27 guidance and strategy in 1QFY27

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Code	Price	Report Date (* Estimate)	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m) HY26	EBITDA Forecast ($m) FY26	Adjusted NPAT Forecast ($m) HY26	Adjusted NPAT Forecast ($m) FY26	Adjusted EPS Forecast (cents) HY26	Adjusted EPS Forecast (cents) FY26	DPS Forecast (cents) Interim HY26 Dividend	DPS Forecast (cents) Final FY26 Dividend	Comments
DEV	$0.24	29/09/2026*	FY	Stuart Howe	$0.41	Buy (Spec)	-	-11.0	-	-10.0	-	-1.8	-	-	Project development company, result not relevant to investment view. Catalyst: Exploration results.
DGT	$2.57	21/08/2026	FY	Andy MacFarlane	$3.40	Buy	57.2	124.9	43.4	73.9	7.9	13.4	6.0	12.0	FY26 guidance underlying EBITDA $125m, growth capex $160-180m, DPS 12c (90-100% payout), and 85mw IT contracted.
DLI	$0.16	25/09/2026*	FY	James Williamson	$0.41	Buy (Spec)	-	-8.2	-	-7.2	-	-1.0	-	-	Project development company. Financial result not relevant to investment thesis.
DMP	$19.73	26/08/2026	FY	Leo Armati	$18.50	Hold	-	338.2	-	120.3	-	127.2	25.0	25.0	FY26 guidance: Underlying NPAT b/w $118-$122m (BPe $120.3m) To look for: First 7-weeks trading update SSSG (cycling -0.9%)
DOC	$0.11	17/08/2026	HY	John Hester	$0.24	Buy	2.6	-	0.5	-	0.1	-	-	-	Progress on recently completed acquistion should be interesting
DRO	$1.82	26/08/2026	HY	Baxter Kirk	$2.50	Buy	1.3	-	-6.8	-	-0.7	-	-	-	Revenue and Gross margin pre-reported and CY26 guided in late July 2026. Focus will be on the degree of the scaling cost base.
DVP	$4.76	September	FY	Joseph House	$6.50	Buy	-	61.6	-	28.1	-	8.2	-	-	Does not report in August. Annual report to be published in September.
DXC	$2.67	10/08/2026	FY	Michael Armstrong	$3.15	Buy	19.5	39.2	14.5	28.8	10.5	20.9	10.5	20.9	Expect commentary around fund-through development pipeline/further opportunities, tenant health, and the ongoing 5% on-market share buyback. Expect soft FY27 earnings guidance predicated on elevated interest rates.
DXI	$2.47	12/08/2026	FY	Andy MacFarlane	$3.00	Buy	37.9	75.2	28.2	55.1	8.9	17.4	8.3	16.6	FY26 guidance is for FFO / share of 17.4c and DPS of 16.6c; BPe and VA consensus both in line
DYL	$1.33	29/09/2026*	FY	James Williamson	$1.90	Hold (Spec)	-	-15.3	-	-9.2	-	-0.9	-	-	Project development company. Financial result not relevant to investment thesis.

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Code	Price	Report Date (* Estimate)	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m) HY26	EBITDA Forecast ($m) FY26	Adjusted NPAT Forecast ($m) HY26	Adjusted NPAT Forecast ($m) FY26	Adjusted EPS Forecast (cents) HY26	Adjusted EPS Forecast (cents) FY26	DPS Forecast (cents) Interim HY26 Dividend	DPS Forecast (cents) Final FY26 Dividend	Comments
EBR	$0.27	12/08/2026*	HY	Martyn Jacobs	$0.90	Buy (Spec)	-30.0	-52.0	-34.0	-59.6	-4.5	-7.0	-	-	1H26 should be peak operating loss. Focus will be on growth in utilisation and progress in deployment to announced hospital contracts.
EGL	$0.10	20/08/2026*	FY	Ritesh Varma	$0.21	Buy	-	8.6	-	3.1	-	0.8	-	-	Following guidance downgrade in May, we look for FY27 guidance.
EIQ	$1.33	31/08/2026*	FY	John Hester	$1.75	Hold (Spec)	-	-9.6	-	-10.2	-	-1.6	-	-	We expect nil revenues from operations, commercialisation update will be relevant
ELD	$5.64	16/11/2026	FY	Jonathan Snape	$6.45	Buy	-	285.9	-	104.5	-	48.9	18.0	36.0	-
ELS	$6.17	26/08/2026*	HY	Baxter Kirk	$8.20	Buy	10.7	-	9.2	-	3.8	-	-	-	10.7 EBIT not EBITDA. BPe underlying NPAT incl. SBC. Revenue and cash costs pre reported.
EMV	$1.60	28/08/2026	FY	Martyn Jacobs	$3.15	Buy (Spec)	-	-8.5	-	-9.1	-	-9.8	-	-	Pre-revenue company with primary focus on progress with pivotal emu trial and Frist Responder feasibility studies
EOL	$14.51	19/08/2026*	FY	Ritesh Varma	$17.10	Buy	-	21.3	-	9.6	-	30.4	-	12.0	ARR growth is the key measure here, guided to 13% in May.
EOS	$6.94	21/08/2026*	FY	Baxter Kirk	$12.60	Buy	20.7	-	10.0	-	-	4.8	-	-	Excludes acquisition costs.
EVN	$11.46	19/08/2026	FY	David Coates	$15.10	Buy	-	3,696.2	-	1,976.4	-	95.9	20.0	50.0	Watch for upside dividend surprise vs consensus 43c
FAL	$0.42	20/10/2026*	FY	Todd Lewis	$1.10	Buy (Spec)	-0.6	-4.4	-0.3	-4.1	-1.9	-1.9	-	-	Exploration / development company, cash $15.4m
FEX	$0.26	20/08/2026*	FY	James Williamson	$0.54	Buy	-	80.4	-	9.9	-	1.3	-	-	Potential for modest dividend contingent upon board discretion.

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Code	Price	Report Date (* Estimate)	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m)		Adjusted NPAT Forecast ($m)		Adjusted EPS Forecast (cents)		DPS Forecast (cents)		Comments
							HY26	FY26	HY26	FY26	HY26	FY26	Interim HY26 Dividend	Final FY26 Dividend	
FHE	$0.19	26/08/2026*	HY	Ritesh Varma	$0.35	Buy	-2.0	-	-1.8	-	-0.3	-	-	-	Looking at development timeline commentary and debt financing.
FLC	$0.07	31/08/2026*	HY	Ritesh Varma	$0.11	Buy (Spec)	1.8	-	0.2	-	0.0	-	-	-	Look for continued SPS + RR revenue growth.
FMG	$17.80	24/08/2026	FY	David Coates	$17.40	Hold	-	8,504.0	-	3,827.3	-	122.7	62.0	113.0	Downside risk on higher costs (diesel), FX and pric realisations
FRS	$0.33	30/09/2026	FY	Todd Lewis	$1.15	Buy (Spec)	16.8	16.8	13.6	11.2	1.9	1.9	-	-	Development/ near term producing company. Recently acquired Edna May. Producer in 2027.
GDG	$4.02	27/08/2026	FY	Hayden Nicholson	$6.20	Buy	-	43.7	-	42.1	-	10.6	-	1.0	Evidentia pre-reported FUM growth of +37%, with average period FUM +16% above opening.
GDI	$0.63	24/08/2026	FY	Andy MacFarlane	$0.85	Buy	31.0	62.2	21.3	42.0	3.9	7.8	2.5	5.0	FY26 guidance is for DPS of 5.0c (through-cycle target; already met), looking for updates on potential asset disposals, performance of Co-Living JV, and potential Broadmeadows perf fee.
GLF	$4.47	24/08/2026	HY	Andy MacFarlane	$5.65	Buy	67.9	137.8	56.4	113.0	14.8	29.7	1.1	2.0	Key focus for the market will be commentary on sales and settlements achieved (CY26 guidance 420 lots; BPe 425 lots), and margin support.
GMD	$5.83	20/08/2026*	FY	Todd Lewis	$9.20	Buy	561.5	1,004.3	325.7	581.4	28.6	51.0	-	-	Beat on produciton, miss on costs. Look for merger with Vault as a key cataly in late 2026.
GMG	$29.87	20/08/2026	FY	Andy MacFarlane	$35.50	Buy	1,172.3	2,758.0	1,203.5	2,670.0	58.5	129.7	15.0	30.0	We forecast a small beat to guidance (10% vs. 9%) driven by profits booked on land uplift for DC projects going into WIP, as well as transaction relisation (Moorrabbin).
GNC	$5.66	12/11/2026	FY	Jonathan Snape	$5.90	Buy	-	228.6	-	38.4	-	17.5	14.0	24.0	-

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Code	Price	Report Date (* Estimate)	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m) HY26	EBITDA Forecast ($m) FY26	Adjusted NPAT Forecast ($m) HY26	Adjusted NPAT Forecast ($m) FY26	Adjusted EPS Forecast (cents) HY26	Adjusted EPS Forecast (cents) FY26	DPS Forecast (cents) Interim HY26 Dividend	DPS Forecast (cents) Final FY26 Dividend	Comments
GNP	$8.85	25/08/2026	FY	Joseph House	$12.80	Buy	-	97.2	-	52.6	-	28.2	2.0	6.5	Given guidance was upgraded in late FY26, we have high confidence in our FY26 estimates. We are expecting FY27 organic EBITDA growth of ~22%.
GTK	$3.08	24/11/2026*	FY	Michael Ardrey	$5.60	Buy	-	15.4	-	6.9	-	6.2	-	-	-
GYG	$25.33	21/08/2026	FY	Leo Armati	$24.50	Buy	-	85.1	-	21.1	-	20.8	7.4	7.3	FY26 guidance: Australia segment underlying EBITDA $85m, +29% on pcp). To look for: First 7-weeks trading update SSSG (cycling +3.7%)
HCW	$0.75	18/08/2026	FY	Andy MacFarlane	$0.95	Buy	22.7	43.2	12.3	22.9	2.2	4.2	-	-	No FY26 guidance given current HSO situation. We assume UHF and HCW distribution to turn back on in 2Q27
HDN	$1.27	13/08/2026	FY	Michael Armstrong	$1.25	Sell	134.7	273.6	92.3	188.5	4.4	9.0	4.3	8.6	Management have previously commented on slowing the annual development starts from $100-$120m to $50-60m, which will limit earnings growth.
HMC	$2.98	26/08/2026	FY	Andy MacFarlane	$3.20	Hold	49.6	178.8	29.1	118.6	7.1	28.7	6.0	12.0	Looking through FY26, where guidance for pre-tax EPS of at least 40c (BPe 40c; VA cons 38.6c), wins for DGT (potential capital distribution), Healthscope approaching resolution, we see HMC turning the corner post challenging 12-24mths.
HUB	$85.71	18/08/2026	FY	Hayden Nicholson	$110.00	Buy	-	213.1	-	130.9	-	157.3	-	42.1	FY26 group operating expenses expected to increase +18-20%. We expect custodial FUA targets to be rolled forward to FY28 (Bell Potter $192.7bn).
HVN	$4.92	28/08/2026	FY	Chami Ratnapala	$6.00	Buy	-	1,093.8	-	443.1	-	35.5	14.5	29.8	One-off expense of $35-38m (as per BPe) to be recognised in FY26 financials
IDX	$2.14	25/08/2026	FY	Martyn Jacobs	$3.80	Buy	-	172.0	-	49.7	-	13.3	3.3	8.3	BPe is slightly above consensus EBITDA ($169m). Focus on incremental MRI contribution and Lung cancer screening, with achievement of 21% margin guidance and cost mitigation. First briefing from new CEO to set agenda.

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Code	Price	Report Date (* Estimate)	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m) HY26	EBITDA Forecast ($m) FY26	Adjusted NPAT Forecast ($m) HY26	Adjusted NPAT Forecast ($m) FY26	Adjusted EPS Forecast (cents) HY26	Adjusted EPS Forecast (cents) FY26	DPS Forecast (cents) Interim HY26 Dividend	DPS Forecast (cents) Final FY26 Dividend	Comments
IGL	$2.85	26/08/2026	FY	Chris Savage	$3.25	Buy	-	153.5	-	52.2	-	33.5	-	8.5	EBITDA, NPAT and EPS forecasts are underlying.
IMD	$3.75	17/08/2026	FY	Joseph House	$4.60	Buy	-	157.1	-	55.1	-	10.2	1.7	3.2	Expecting FY27 outlook to be generally positive; focus will be on cost and margin expectations.
IMM	$0.05	28/08/2026*	FY	Thomas Wakim	$0.07	Hold (Spec)	-	-55.9	-	-55.4	-	-3.8	-	-	Pre-revenue, clinical-stage biotech. $69m cash balance at 30-June-2026.
IMU	$0.08	31/08/2026	FY	John Hester	$0.25	Buy (Spec)	-	-57.3	-	-59.9	-	-14.4	-	-	-
ING	$2.19	21/08/2026	FY	Jonathan Snape	$2.10	Hold	-	188.6	-	58.7	-	19.6	4.0	10.0	FY26e EBITDAL guidance of $180-210m and includes $7m of additional distribution costs
INR	$0.11	3/08/2026	FY	Stuart Howe	$0.40	Buy (Spec)	-	-10.0	-	-4.0	-	6.7	-	-	Project development company, result not relevant to investment view. Catalyst: Project level sell-down progress.
IPD	$0.01	28/08/2026	FY	Martyn Jacobs	$0.02	Buy (Spec)	-	-18.2	-	-23.5	-	-0.7	-	-	4Q26 result is more important in understanding performance. Looking for Sozo volume >40 units for June qtr.
IPG	$4.80	14/08/2026	FY	Joseph House	$6.20	Buy	-	55.0	-	30.5	-	29.3	6.8	14.6	FY27 guidance to be qualitative rather than quantative and focussing on strong momentum in the Data Centre market.
IPX	$3.01	30/09/2026*	FY	Stuart Howe	$5.60	Buy (Spec)	-	-41.0	-	-45.0	-	-19.3	-	-	Project development company, result not relevant to investment view. Catalyst: Commercial agreement & market updates.
IRI	$0.30	27/08/2026	FY	Chris Savage	$0.38	Buy	-	-3.1	-	-0.1	-	-0.1	-	-	Forecasts are statutory.
ITS	$0.26	28/08/2026	FY	Chris Savage	$0.58	Buy	-	2.7	-	-4.6	-	-2.4	-	-	EBITDA forecast is underlying. NPAT and EPS forecasts are statutory.

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Code	Price	Report Date (* Estimate)	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m) HY26	EBITDA Forecast ($m) FY26	Adjusted NPAT Forecast ($m) HY26	Adjusted NPAT Forecast ($m) FY26	Adjusted EPS Forecast (cents) HY26	Adjusted EPS Forecast (cents) FY26	DPS Forecast (cents) Interim HY26 Dividend	DPS Forecast (cents) Final FY26 Dividend	Comments
JBH	$82.42	17/08/2026	FY	Chami Ratnapala	$87.00	Buy	-	1,000.4	-	482.8	-	438.5	210.0	330.6	BPe ~1% below Consensus for FY26e
JIN	$7.31	27/08/2026	FY	Baxter Kirk	$7.10	Hold	-	83.2	-	40.7	-	64.5	12.0	24.0	-
KGN	$4.26	24/08/2026	FY	Chami Ratnapala	$3.30	Hold	-	40.8	-	18.2	-	17.4	8.0	12.8	Guidance of Group Adjusted EBITDA margins of 6-9% for FY26
KYP	$0.15	6/08/2026	FY	Chris Savage	$0.36	Buy	-	5.5	-	2.0	-	0.5	-	-	Forecasts are statutory.
LDX	$0.11	28/08/2026	FY	Martyn Jacobs	$0.25	Buy	-	-7.3	-	-11.5	-	-1.2	-	-	Early US rollout data will be limited. Focus will be on outlook for US rollout ahead of US flu season which should be peak for FebriDx ordering cycle. Looking fo rfurther Urgent Care sign-ups.
LGI	$2.39	21/08/2026	FY	Ritesh Varma	$4.50	Buy	-	21.6	-	8.7	-	8.8	-	2.6	With low commodity prices, FY27 EBITDA guidance will be interesting.
LIC	$5.18	21/08/2026	FY	Andy MacFarlane	$5.50	Hold	22.4	50.8	9.5	28.9	7.8	23.8	-	-	Looking for direction / confidence on FY27 settlements, possible guidance, and any improvement (if so) on the market outlook.
LNQ	$0.34	23/09/2026*	FY	David Coates	$0.90	Buy	-	-4.2	-	-4.4	-	-2.2	-	-	Exploration / development company, cash $16m
LNW	$115.97	5/08/2026	HY	Baxter Kirk	$190.00	Buy	-	367.5	-	114.5	-	143.8	-	-	2Q26 - Management has previously guided to a 2H EBITDA growth skew
LOV	$24.75	26/08/2026*	FY	Chami Ratnapala	$33.50	Hold	-	287.9	-	90.6	-	81.2	53.0	78.9	BPe ~8% below Consensus at EBIT level for FY26e
LTR	$0.99	31/08/2026	FY	Stuart Howe	$1.90	Buy	-	222.0	-	34.0	-	1.2	-	-	FY26 result to reflect ramp-up year & transition from open pit to UG mining. Key catalyst: Expansion study & FID by late Sep'26.

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Code	Price	Report Date (* Estimate)	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m) HY26	EBITDA Forecast ($m) FY26	Adjusted NPAT Forecast ($m) HY26	Adjusted NPAT Forecast ($m) FY26	Adjusted EPS Forecast (cents) HY26	Adjusted EPS Forecast (cents) FY26	DPS Forecast (cents) Interim HY26 Dividend	DPS Forecast (cents) Final FY26 Dividend	Comments
MAD	$6.97	25/08/2026	FY	Joseph House	$9.70	Buy	-	121.3	-	67.2	-	32.8	4.8	5.5	Focus will be on FY27 revenue and NPAT guidance. BPe is $1,114m and $76m, respectively.
MI6	$0.62	25/09/2026*	FY	David Coates	$1.40	Buy	-	-12.9	-	-12.2	-	-0.6	-	-	Exploration / development company, cash $211m
MIN	$57.73	27/08/2026	FY	James Williamson	$75.00	Buy	-	2,502.9	-	772.0	-	391.4	-	65.1	See potential for dividend with balance sheet targets set out in the capital allocation framework now within range.
MMS	$19.63	28/08/2026	FY	Hayden Nicholson	$19.90	Buy	-	178.6	-	106.8	-	153.4	-	65.0	Outlook indicates higher 2H profits, driven by broad-based customer growth, with 3Q26 new vehicle lease growth of +7%.
MND	$29.55	25/08/2026	FY	Joseph House	$32.00	Hold	-	224.0	-	126.6	-	126.1	49.0	105.0	Revenue outlook likely to be qualitative. Focus will be on comments relating to tendering activity and operating margin expectations.
MSB	$2.03	31/08/2026	FY	John Hester	$4.45	Buy	-	-25.2	-	-67.5	-	-5.3	-	-	Company may provide further granularity on commercialisation progress for Ryoncil
MVF	$0.69	24/08/2026	FY	Martyn Jacobs	$0.75	Hold	-	51.4	-	15.1	-	4.3	1.2	2.3	Pre-released guidance downgrade. Focus will be on stabiling the business and improving the key Victorian segment. Cost out initiative potential to improve profitability.
MVP	$0.43	20/08/2026*	FY	Martyn Jacobs	$1.00	Buy	-	1.0	-	-1.5	-	-1.4	-	-	Focus on completion of EU expansion in labelling, Australian healthcare economic analysis and outlook for rev. / earnings growth.
MYG	$2.12	27/08/2026	FY	Joseph House	$3.20	Buy	-	15.1	-	9.0	-	8.2	2.0	5.2	Expecting outlook commentary to be bullish given record WIH entering FY27 and generally positive indicators in key construction markets.
NAN	$3.18	25/08/2026	FY	John Hester	$3.60	Hold	-	22.9	-	15.9	-	5.2	-	-	Expecting another lack lustre result with modest revenue growth only
NCK	$16.05	7/08/2026	FY	Chami Ratnapala	$22.00	Buy	-	180.8	-	75.7	-	88.6	39.0	60.9	BPe ~2% below Consensus at NPAT level for FY26e

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Code	Price	Report Date (* Estimate)	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m) HY26	EBITDA Forecast ($m) FY26	Adjusted NPAT Forecast ($m) HY26	Adjusted NPAT Forecast ($m) FY26	Adjusted EPS Forecast (cents) HY26	Adjusted EPS Forecast (cents) FY26	DPS Forecast (cents) Interim HY26 Dividend	DPS Forecast (cents) Final FY26 Dividend	Comments
NEU	$18.59	27/08/2026*	HY	Thomas Wakim	$23.50	Buy	-6.3	-	-0.3	-	-0.3	-	-	-	Royalty revenue will be informed by Acadia's Q2 result on 5th August.
NHC	$5.15	15/09/2026	FY	James Williamson	$5.00	Hold	-	490.7	-	151.4	-	18.0	-	10.0	Upside risk to earnings estimates with potential for a strong 4Q (4Q quarterly report scheduled 17-Aug-26; July year-end).
NIC	$0.82	26/08/2026	FY	David Coates	$1.45	Buy	255.0	604.0	126.0	316.0	2.9	7.3	-	-	Balance sheet deleveraging story CY27
NOU	$0.12	20/08/2026	FY	Jonathan Snape	$0.12	Hold	-	64.4	-	37.0	-	13.4	-	-	EBITDA guidance of $61-63m
NWL	$22.43	26/08/2026	FY	Hayden Nicholson	$30.00	Buy	-	195.3	-	132.4	-	54.0	-	23.0	FY26 EBITDA margins expected to land at 49%, with $12m invested in capitalised software.
OCC	$0.71	TBA	FY	Brenton Anderson	$1.19	Buy (Spec)	-	-12.3	-	-11.0	-	-4.2	-	-	Company doesn't provide guidance. $44.1m funds available at 30-June-2026
OMA	$0.51	28/09/2026*	FY	Stuart Howe	$1.40	Buy (Spec)	-	-10.0	-	5.0	-	1.2	-	-	Project development company, result not relevant to investment view. Catalyst: Taroom Trough appraisal activity.
ONE	$0.17	13/08/2026*	HY	Martyn Jacobs	$0.42	Buy (Spec)	-4.0	-7.9	-4.5	-9.0	-0.5	-1.0	-	-	Aiming for >20% top line growth while continuing to narrow operating losses.
PAR	$0.18	31/08/2026*	FY	John Hester	$0.42	Buy (Spec)	-	-49.0	-	-49.0	-	-8.5	-	-	-
PDN	$9.41	27/08/2026*	FY	James Williamson	$14.80	Buy	-	71.1	-	5.1	-	0.6	-	-	All figures in US$.
PFP	$3.27	24/08/2026	FY	Chami Ratnapala	$3.80	Buy	-	54.6	-	19.5	-	14.1	7.5	11.9	Guidance of $225-230m in revenue and $54.5-56.5m in operating EBITDA for FY26

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Code	Price	Report Date (* Estimate)	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m) HY26	EBITDA Forecast ($m) FY26	Adjusted NPAT Forecast ($m) HY26	Adjusted NPAT Forecast ($m) FY26	Adjusted EPS Forecast (cents) HY26	Adjusted EPS Forecast (cents) FY26	DPS Forecast (cents) Interim HY26 Dividend	DPS Forecast (cents) Final FY26 Dividend	Comments
PGC	$0.13	27/08/2026*	FY	John Hester	$0.17	Hold	-	95.1	-	22.2	-	1.3	-	-	PGC had a poor year in FY26. Looking forward to a substantial turnaround in FY27.
PLS	$4.08	24/08/2026	FY	James Williamson	$4.70	Hold	-	1,148.3	-	563.9	-	17.5	-	4.0	See potential for modest dividend with strong cash generation, although at risk with potential large capital investment program with P2000 Project.
PME	$164.69	18/08/2026	FY	John Hester	$226.00	Buy	-	195.1	-	138.4	-	138.5	32.0	70.0	Focus will be on timing of revenues from the two major new clients
PMT	$0.42	14/08/2026*	HY	Stuart Howe	$0.97	Buy (Spec)	-	-	-	-	-	-	-	-	Project development company, result not relevant to investment view. Catalyst: Project permitting & optimisation updates.
PMV	$13.47	24/09/2026*	FY	Chami Ratnapala	$26.50	Buy	-	260.4	-	156.2	-	98.2	45.0	79.7	Guidance Retail EBIT (Pre-AASB 16) for FY26 at $183m (BPe at guidance)
PNR	$2.02	28/09/2026*	FY	David Coates	$2.25	Hold	-	316.7	-	173.1	-	44.1	-	-	Downside risk on higher costs from 2HFY26
PNV	$0.88	26/08/2026	FY	John Hester	$1.00	Hold	-	8.2	-	3.8	-	0.6	-	-	Growth rate really slowed in 2H26, stock has de-rated
PPS	$0.73	TBA	FY	Hayden Nicholson	$1.20	Buy	-	31.9	-	18.1	-	3.8	-	1.4	Pre-reported custodial FUA growth of +11%, with average period FUA +9% higher
PWH	$9.98	20/08/2026	FY	Chris Savage	$9.25	Hold	-	39.4	-	15.8	-	15.7	-	4.5	Forecasts are statutory.
PYC	$1.82	28/08/2026*	FY	Thomas Wakim	$2.30	Buy (Spec)	-	-59.5	-	-52.2	-	-5.3	-	-	Pre-revenue, clinical-stage biotech. $670m cash balance at 30-June-2026.
RAD	$0.01	31/08/2026*	FY	John Hester	$0.06	Buy (Spec)	-	-46.1	-	-43.1	-	-1.3	-	-	RAD is expected to complete a partering deal in 2HCY26 for RAD101

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Code	Price	Report Date (* Estimate)	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m) HY26	EBITDA Forecast ($m) FY26	Adjusted NPAT Forecast ($m) HY26	Adjusted NPAT Forecast ($m) FY26	Adjusted EPS Forecast (cents) HY26	Adjusted EPS Forecast (cents) FY26	DPS Forecast (cents) Interim HY26 Dividend	DPS Forecast (cents) Final FY26 Dividend	Comments
REA	$160.00	6/08/2026	FY	Michael Ardrey	$137.00	Sell	-	1,043.8	-	625.5	-	475.5	124.0	266.3	Strong listings late in FY26 providing some momentum into early FY27 ; expecting outlook to focus on listings and margin against a challenging operating environment
RFF	$2.19	21/08/2026*	FY	Jonathan Snape	$2.50	Buy	-	78.8	-	45.8	-	11.8	5.9	11.7	FY26 AFFO guidance of 11.72pu
RFG	$0.86	20/08/2026*	FY	Chami Ratnapala	$0.74	Hold (Spec)	-	20.0	-	5.4	-	8.7	-	-	Guidance of Und.EBITDA at $20-21m for FY26
RGN	$2.40	18/08/2026	FY	Andy MacFarlane	$2.75	Buy	125.9	255.4	91.4	184.9	7.9	16.0	6.9	14.1	Strong treasury has put RGN in good stead, with new CEO Greg Chubb joining during the period
RIV	$1.42	31/08/2026	HY	Jonathan Snape	$1.61	Buy	-	13.1	-	8.4	-	5.3	3.7	7.4	No guidance. Lease levels are higher in 2H26e
RMY	$0.03	31/8/2026*	FY	Michael Ardrey	$0.07	Buy (Spec)	-	0.4	-	-0.7	-	-0.1	-	-	Revenue pre-reported, grew 10% to $22.7m; top-down brokerage deal momentum strong, but yet to convert into meaningful revenue
RPL	$2.78	24/08/2026	HY	Hayden Nicholson	$4.80	Buy	151.0	-	90.0	-	24.4	-	7.0	-	Guidance floor of at least $110m in management fees, $115m in performance fees, and $90m NPAT.
RRL	$6.15	21/08/2026	FY	David Coates	$8.45	Buy	-	1,511.8	-	831.0	-	109.7	15.0	34.0	Higher costs and investment CAPEX in FY27
SEK	$14.68	18/08/2026	FY	Michael Ardrey	$18.58	Buy	-	541.6	-	200.1	-	56.0	27.0	52.0	Job ad volumes to be soft, potential for price to provide positive result. Margin and potential for Growth Fund realisation to support result/outlook
SGH	$44.43	11/08/2026	FY	Joseph House	$50.00	Buy	-	2,104.2	-	952.1	-	233.1	32.0	66.0	Consensus FY27 EBIT growth is low-to-mid single-digit. We expect FY27 Group EBIT growth guidance to be consistent with consensus.
SHL	$21.84	20/08/2026	FY	Martyn Jacobs	$28.75	Buy	-	1,962.0	-	661.6	-	129.1	45.0	109.0	Slightly above consensus EBITDA at $1.934b. Initiatives from US operaitonal review, margin

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Code	Price	Report Date (* Estimate)	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m) HY26	EBITDA Forecast ($m) FY26	Adjusted NPAT Forecast ($m) HY26	Adjusted NPAT Forecast ($m) FY26	Adjusted EPS Forecast (cents) HY26	Adjusted EPS Forecast (cents) FY26	DPS Forecast (cents) Interim HY26 Dividend	DPS Forecast (cents) Final FY26 Dividend	Comments
															management and further indications on sale&leaseback opportunities.
SHV	$4.19	25/11/2026*	FY	Jonathan Snape	$5.30	Buy	-	113.9	-	49.3	-	34.9	3.5	10.0	-
SIG	$2.97	27/08/2026	FY	John Hester	$3.00	Hold	-	1,165.8	-	746.1	-	6.5	2.0	4.5	Expecting another very strong result for top line growth
SIQ	$12.99	27/08/2026	HY	Hayden Nicholson	$11.50	Buy	72.6	-	7.0	-	32.6	-	21.7	-	1Q26 average monthly revenue growth of +8%, novated leasing settlements up +7%, and order growth of +22%. Our estimates anticipate an acceleration to +9% revenue growth.
SKG	$1.30	14/08/2026	FY	Michael Armstrong	$1.50	Hold	60.4	124.1	40.4	81.5	3.1	6.2	3.1	6.2	Looking for clarity regarding ABG's 20% stake and the 40% stake held by the Kirsch family. At announcement of the de-staple, SKG guided to +6% earnings growth on cost savings.
SKY	$0.24	18/09/2026*	FY	James Williamson	$0.30	Buy (Spec)	-	-4.2	-	-3.8	-	-0.4	-	-	Project development company. Financial result not relevant to investment thesis.
SLD	$0.43	27/08/2026*	FY	Thomas Wakim	$1.60	Buy (Spec)	-	-108.4	-	-119.0	-	-0.4	-	-	Revenue pre-released at quarterly. Outside of Prospectus forecasts, guidance only given for GM, which is >46%.
SM1	$0.30	29/09/2026*	FY	Jonathan Snape	$0.39	Hold	-	18.0	-	-66.3	-	-11.0	-	-	-
SMI	$0.50	29/09/2026*	FY	David Coates	$1.70	Buy (Spec)	-	-7.2	-	-6.8	-	-0.8	-	-	Exploration / development company, cash $188m
SNS	$0.03	27/08/2026	FY	Chris Savage	$0.08	Buy	-	2.1	-	0.9	-	0.1	-	-	EBITDA forecast is underlying. NPAT and EPS forecasts are statutory.
SNT	$0.03	27/08/2026*	FY	Thomas Wakim	$0.06	Buy (Spec)	-	-10.5	-	-10.6	-	-0.5	-	-	Pre-revenue, clinical-stage biotech. $13.5m cash balance at 30-June-2026.

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Code	Price	Report Date (* Estimate)	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m) HY26	EBITDA Forecast ($m) FY26	Adjusted NPAT Forecast ($m) HY26	Adjusted NPAT Forecast ($m) FY26	Adjusted EPS Forecast (cents) HY26	Adjusted EPS Forecast (cents) FY26	DPS Forecast (cents) Interim HY26 Dividend	DPS Forecast (cents) Final FY26 Dividend	Comments
SNZ	$7.00	27/08/2026	HY	Andy MacFarlane	$14.40	Buy	115.2	279.8	101.9	236.5	42.2	97.8	12.5	25.0	CY26 guidance for 750-850 new homes build rate under ORA across Aus and NZ (vs. 693 in CY25). Market focused on net debt position.
SRG	$3.38	18/08/2026	FY	Joseph House	$4.25	Buy	-	167.2	-	74.0	-	12.9	3.0	6.5	FY27 EBITDA guidance was initially set in June 2026. We anticipate this guidance to be reiterated.
STP	$0.15	19/08/2026	FY	Leo Armati	$0.29	Hold	-	0.4	-	0.1	-	-	-	-	Key focus on GM given pullback in promotional spend (BPe 72.1% vs. 76.4% in pcp) Inventory management given expansion in product range and SKU's
STX	$0.10	28/09/2026*	FY	Stuart Howe	$0.16	Buy (Spec)	-	17.0	-	-35.0	-	-1.0	-	-	Finanial result based on Walyering production only; key to company value is South Erregulla power plant (Commissioning Oct26) and pre-FID West Erregulla JV.
SXE	$4.38	19/08/2026	FY	Joseph House	$5.40	Buy	-	75.3	-	42.0	-	15.7	2.5	8.5	FY27 EBITDA guidance was initially set in June 2026. We anticipate this guidance to be reiterated.
TLS	$5.02	13/08/2026	FY	Chris Savage	$5.10	Hold	-	8,966.0	-	2,328.7	-	20.6	-	10.5	EBITDA, NPAT and EPS forecasts are underlying.
TLX	$14.28	20/08/2026	HY	John Hester	$19.00	Buy	44.9	-	26.6	-	-	7.8	-	-	Revenues pre released, focus will be on cash and clinical update
TNE	$31.02	N/A	N/A	Chris Savage	$34.25	Hold	-	-	-	-	-	-	-	-	-
TPW	$5.55	19/08/2026	FY	Chami Ratnapala	$7.00	Buy	-	21.3	-	8.4	-	6.5	-	-	Guidance of $665-675m in revenue (up 11% to 12%) and EBITDA of $20-22m for FY26
TRJ	$0.21	27/08/2026*	FY	Martyn Jacobs	$0.75	Buy	-	14.0	-	2.6	-	1.7	-	-	Pre-released downgraded guidance. Macro risks impacting growth. Further downside risk relative to BPe EBITDA growth of c.38%
TTT	$0.18	01/09/2026*	FY	Stuart Howe	$0.46	Buy (Spec)	-	-22.0	-	-24.0	-	-1.6	-	-	Project development company, result not relevant to investment view. Catalyst: Commercial agreement & market updates.

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

Code	Price	Report Date (* Estimate)	Reporting Year End	Analyst	Target Price	Recommendation	EBITDA Forecast ($m) HY26	EBITDA Forecast ($m) FY26	Adjusted NPAT Forecast ($m) HY26	Adjusted NPAT Forecast ($m) FY26	Adjusted EPS Forecast (cents) HY26	Adjusted EPS Forecast (cents) FY26	DPS Forecast (cents) Interim HY26 Dividend	DPS Forecast (cents) Final FY26 Dividend	Comments
UNI	$7.39	20/08/2026	FY	Chami Ratnapala	$10.50	Buy	-	104.0	-	39.8	-	50.7	26.0	36.9	Guidance of $61.5-64.5m EBITA for FY26
VFY	$3.70	04/08/2026*	FY	Martyn Jacobs	$5.15	Buy (Spec)	-	-17.8	-	-17.1	-	-22.4	-	-	Pre-revenue company, with primary focus on attaining FDA clearance by end of CY26 for blood patelets and Red Blood Cells, and continuing to build market interest in its Cryopreservation technology.
VMM	$3.30	29/09/2026*	FY	Todd Lewis	$4.30	Buy (Spec)	-1.5	-3.0	-0.5	-2.0	-1.1	-3.9	-	-	Exploration / development company, cash $20.5m
VUL	$2.62	11/09/2026	HY	Stuart Howe	$4.50	Buy (Spec)	-	-	-	-	-	-	-	-	Project development company, result not relevant to investment view. Catalyst: Project development updates; lithium market news.
WA1	$11.13	28/09/2026*	FY	Todd Lewis	$27.20	Buy (Spec)	-14.7	-18.9	-12.6	-14.9	-0.2	-0.2	-	-	Exploration / development company, cash $124m
WC8	$0.33	23/09/2026*	FY	James Williamson	$1.00	Buy (Spec)	-	-10.7	-	-9.5	-	-0.7	-	-	Project development company. Financial result not relevant to investment thesis.
WHC	$7.05	19/08/2026	FY	James Williamson	$8.05	Hold	-	1,321.3	-	282.5	-	34.2	-	7.0	Expect equal $ value of dividend allocated to share buy-back (i.e. $55m dividend; $55m share buy-back)
WOW	$40.14	26/08/2026	FY	Jonathan Snape	$35.50	Hold	-	6,119.9	-	1,509.5	-	123.6	45.0	91.0	1) Australian Food EBIT is expected to grow at mid-high single digit rates; and (2) 2H26e NZ EBIT is expected to be modestly down YoY in NZD terms
WRK	$0.07	20/08/2026	FY	Hayden Nicholson	$0.12	Buy (Spec)	-	-5.6	-	-7.6	-	-0.4	-	-	EBITDA estimates are before share based payments. FY26 EBITDA is expected to be -$6m.
WTC	$36.74	26/08/2026	FY	Chris Savage	$71.75	Buy	-	561.0	-	160.4	-	69.0	-	8.0	Forecasts are in USD/USC. Forecasts are statutory.

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*

							EBITDA Forecast ($m)		Adjusted NPAT Forecast ($m)		Adjusted EPS Forecast (cents)		DPS Forecast (cents)		
Code	**Price**	**Report Date (** Estimate*)**	**Reporting Year End**	**Analyst**	**Target Price**	**Recommendation**	**HY26**	**FY26**	**HY26**	**FY26**	**HY26**	**FY26**	**Interim HY26 Dividend**	**Final FY26 Dividend**	**Comments**
WTM	$0.48	08/09/2026*	HY	David Coates	$1.05	Buy (Spec)	-	-20.4	-	-21.4	-	-5.9	-	-	Exploration / development company, cash $58m

* Reporting dates are estimates ** Prices at close of 3 August 2026 **Source**: Bloomberg, IRESS, Bell Potter *Last updated 3 August 2026.*